



Update on *Chlamydia trachomatis* Vaccinology

Luis M. de la Maza,^a Guangming Zhong,^b Robert C. Brunham^c

Department of Pathology and Laboratory Medicine, University of California, Irvine, Irvine, California, USA^a;
Department of Microbiology and Immunology, University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA^b; Vaccine Research Laboratory, University of British Columbia Center for Disease Control, Vancouver, British Columbia, Canada^c

ABSTRACT Attempts to produce a vaccine to protect against *Chlamydia trachomatis*-induced trachoma were initiated more than 100 years ago and continued for several decades. Using whole organisms, protective responses were obtained. However, upon exposure to *C. trachomatis*, disease exacerbation developed in some immunized individuals, precluding the implementation of the vaccine. Evidence of the role of *C. trachomatis* as a sexually transmitted pathogen started to emerge in the 1960s, and it soon became evident that it can cause acute infections and long-term sequelae in women, men, and newborns. The main focus of this minireview is to summarize recent findings and discuss formulations, including antigens, adjuvants, routes, and delivery systems for immunization, primarily explored in the female mouse model, with the goal of implementing a vaccine against *C. trachomatis* genital infections.

KEYWORDS *Chlamydia trachomatis* vaccines, *Chlamydia muridarum*, antigens, adjuvants, routes of immunization, delivery systems, *Chlamydia trachomatis*, vaccinology

Chlamydiae infections are widespread throughout the animal kingdom (1–3). Until recently, trachoma was thought to be the most common clinical manifestation in humans (1, 2). Trachoma likely first appeared in China and Mesopotamia (~2,700 B.C.) and then spread to the Middle East and the Mediterranean region (1, 2, 4).

HISTORICAL BACKGROUND

In 1907, Halberstaedter and von Prowazek (5), using Giemsa stain, first described the presence of intracytoplasmic inclusions in conjunctival scrapings from monkeys. However, it was not until 1957 that Tang et al. (6, 7), utilizing chicken embryos, isolated *Chlamydia* from humans with trachoma, although the lymphogranuloma strains have been grown in the yolk sac since 1942 (2, 8).

In 1913, a group in Tunis, led by Nicolle, initiated vaccine studies in humans and nonhuman primates (9). Resistance to rechallenge was observed in some individuals, but in others, inconclusive results occurred. Major efforts to produce a vaccine using live or inactivated *Chlamydia* occurred after the isolation of the organisms by Tang et al. (6, 7). Four research groups (1, 2, 4) performed vaccine trials and reached similar conclusions: some vaccine formulations were protective for a period of 1 to 3 years, the protection was serovar/serogroup specific, and certain immunized individuals, upon reexposure, developed more-severe disease than the placebo-treated groups (8, 10–16). In a few instances, a higher attack rate was observed in vaccinated children than in controls (17, 18). Although Bietti's laboratory manufactured a vaccine, it was never implemented in humans (16).

Improvements in sanitary and hygienic conditions have resulted in the disappearance of trachoma from most parts of the world. In 1993, with the goal to eradicate trachoma by 2020, the WHO implemented the SAFE strategy (2, 19). This SAFE plan

Accepted manuscript posted online 22 February 2017

Citation de la Maza LM, Zhong G, Brunham RC. 2017. Update on *Chlamydia trachomatis* vaccinology. *Clin Vaccine Immunol* 24:e00543-16. <https://doi.org/10.1128/CVI.00543-16>.

Editor Christopher J. Papasian, UMKC School of Medicine

Copyright © 2017 American Society for Microbiology. All Rights Reserved.

Address correspondence to Luis M. de la Maza, lmdelama@uci.edu.

includes surgery for trichiasis, antibiotic treatment of active trachoma, facial cleanliness, and environmental improvements focusing on providing clean water supply and toilets and reducing the number of flies in the affected areas.

The presence of *Chlamydia trachomatis* in the genital tract was first indirectly described when a nongonococcal, or amicrobiana, ophthalmia was observed in newborns (20). In 1910, Heymann (21) noted the presence of inclusions in samples from the cervix of the mother and the urethra of the father of an infant with inclusion blennorrhoea. It is even possible that the identification of *Chlamydia* in the genital tract was described earlier as the cause of an amicrobial urethritis (22). Using the yolk sac technique, Jones et al. (23) first recovered *C. trachomatis* from the cervix of a mother with pelvic inflammatory disease (PID). In the 1970s, the introduction of tissue culture techniques greatly improved the ability to isolate *Chlamydia* from the genital tracts of males and females and the eyes of newborns (1, 2).

C. trachomatis is now recognized as the most common sexually transmitted bacterial infection, with approximately 100 to 150 million new cases occurring each year worldwide, affecting 68 million females (24–26). Most of the infections (70 to 80%) in women are asymptomatic; however, it is estimated that 5 out of 1,000 will develop tubal factor infertility (27–29). The long-term sequelae of a *C. trachomatis* infection in females with PID include chronic abdominal pain, ectopic pregnancy, and infertility (27, 29–37). Screening and treating females may increase the rates of reinfection but reduces the incidence of PID (31, 38–40). In males, epididymitis, but not infertility, is the most severe complication (1, 41). Reactive arthritis (Reiter's syndrome [urethritis, conjunctivitis, and arthritis]) has also been associated with *Chlamydia* (1, 41). In females, most cases of upper genital pathology are due to a single episode of PID. For example, in the pioneering work by Westrom et al. (30), 1,844 women with laparoscopically verified PID and 657 women with normal laparoscopic results were studied over a period of several years. Of the 1,241 women who had episodes of PID, 141 were not able to conceive. Tubal factor infertility was associated with the severity and number of PID episodes. The majority of women who were not able to conceive, 56% (79/141), had a single PID episode, and in most of them, 62% (49/79), the episode was severe. The number of PID episodes also affected the chances of developing tubal infertility. Of the individuals who had a single episode, 8.0% (79/991) became infertile, while 19.5% (36/185) of those who had two episodes and 40.0% (26/65) of patients who had three or more episodes were infertile. The ectopic pregnancy rates for the first pregnancy after index laparoscopy were 1.4% in controls and 9.1% among patients. Prevention of these long-term sequelae is the principal goal of a vaccine (26, 42–51).

IMMUNITY TO *C. TRACHOMATIS* GENITAL INFECTIONS

Natural immunity in humans. It is well-known that genital chlamydial infections are more frequent in young sexually active individuals, between the ages of 15 to 20, than in older persons (24, 52, 53). This finding has been interpreted as evidence of naturally induced protective immunity. Some clinical and experimental evidence supports this suggestion. For example, in sex workers, resistance to infection correlates with duration of prostitution, independently of age, indicating development of acquired immunity (54). Geisler et al. (55) also showed that natural immunity occurs in females with a *C. trachomatis* genital tract infection. Because antibiotic treatment interfered with the development of natural immunity, individuals who were not treated with antibiotics had fewer reinfections than those who were treated with antibiotics. However, it is important to note that, at least in mice, resistance to a primary genital infection increases with age, suggesting that some physiological processes may account for a lower prevalence of chlamydial infections in older individuals (56, 57).

Use of *Chlamydia muridarum* versus *C. trachomatis* in vaccinology studies. The *C. muridarum* isolate, previously called *C. trachomatis* mouse pneumonitis (MoPn), has been extensively utilized to perform studies in mice (44, 45, 58–60). At the genomic level, *C. trachomatis* and *C. muridarum* are highly orthologous, and thus, it is thought that findings in mice will correlate well with observations in humans (61). There are,

however, significant differences in the pathogenicity of *C. trachomatis* versus *C. muridarum* in the mouse model.

Following a vaginal challenge, *C. trachomatis* serovars (A to K) and *C. muridarum* produce quite different acute and chronic diseases in mice. In animals not pretreated with depot-medroxyprogesterone acetate (DMPA), depending on the strain, stage of the estrous cycle, and age of the mice, different doses of *C. muridarum* (50% infective doses [ID₅₀] of ~10⁴ to >10⁷ inclusion-forming units [IFU]) produce severe infection and infertility, while *C. trachomatis* does not do so (56, 57, 60, 62). When pretreated with DMPA, all strains of mice tested so far, with the exception of A/J and DBA/2J mice, develop severe infection and long-term sequelae following a vaginal challenge with a low dose of *C. muridarum* (ID₅₀ of ~200 IFU) (45, 63–67). In contrast, a vaginal infection with *C. trachomatis* in mice pretreated with DMPA induces only mild, short infections and no long-term upper genital pathology, i.e., hydrosalpinx and/or infertility (32, 63, 68–72). Even in the highly susceptible C3H/HeJ mice that have a mutated nonfunctional Toll-like receptor 4 (TLR4), a vaginal infection with *C. trachomatis* serovar D (strain UW-3Cx) does not elicit long-term tubal pathology (73).

Two publications have reported infertility, without hydrosalpinx formation, following single or multiple vaginal infections with very high doses (~10⁶ or 10⁷ IFU) of *C. trachomatis* serovar D or E in mice pretreated with DMPA (74, 75). The lack of hydrosalpinx in these mice suggests that no gross long-term damage was produced in the fallopian tube, and therefore, another mechanism(s), which may or may not be relevant to humans, had to account for the infertility. Hadad et al. (76) recently reported infertility in mice following a vaginal challenge with 3 × 10⁴ IFU of a clinical serovar D isolate. The histopathological findings were not discussed. The apparent high virulence of this serovar D isolate is unusual and needs confirmation.

Sturdevant and Caldwell challenged the validity of using *C. trachomatis* in vaccinology (77). These authors reported that C57BL/6 Rag1^{-/-} mice, which lack mature T- and B-cell immunity, treated with DMPA cleared a vaginal infection with *C. trachomatis* serovar D (D-LC), suggesting that innate immunity is sufficient to control the infection. Interestingly, C3H/HeN male mice with severe combined immunodeficiency (SCID) cannot control a urethral challenge with *C. trachomatis* serovar D (UW-3/Cx), while the wild-type (WT) mice can (78). Finally, following transcervical, intrauterine, or intrabursal infections, in mice pretreated with DMPA, not all *C. trachomatis* serovars/isolates induce infertility in most strains of animals, while *C. muridarum* does (79–87).

In conclusion, in our opinion, further testing of *C. trachomatis* isolates is needed to validate their use in vaccine studies. The production of a humanized mouse model could help to address some of the limitations (88). In the meantime, *C. muridarum* allows us to reproduce in mice the mild, severe acute, and chronic infections that *C. trachomatis* produces in humans. The main shortcoming of *C. muridarum* is the lack of isolates that will allow testing for cross-serovar protection.

Immunity to *C. muridarum* in the mouse model. Characterizing immune responses in humans is extremely difficult for many reasons (1, 32, 59). Each individual has a different immunogenetic background. Infection can occur at birth or shortly thereafter. The infection can be asymptomatic. There is cross-reactivity among different species of *Chlamydia*. Keeping track of sexual behavior in humans is difficult. Therefore, most of what we know about protective immunity against chlamydial infections is based on work performed in the mouse model. Using WT and knockout (KO) mice for genes involved in cellular and humoral immune responses, cytokines and chemokines, and passive transfer of T cells and antibodies, immune components that play a role in protection against primary and secondary genital *C. muridarum* challenges have been determined (44, 45). From these studies, it was found that major histocompatibility complex class II (MHC-II)-restricted CD4⁺ T cells are required for protective immunity, while MHC-I-restricted CD8⁺ T cells are not essential for resolution of a primary infection or protection against a genital reinfection (64, 89–91). Human data support these findings. For example, HIV-1-infected patients, who have low CD4⁺ T-cell counts,

are at a higher risk of becoming genitally infected with *C. trachomatis* and developing long-term sequelae than healthy individuals (92). Although CD8⁺ T cells play a critical role in protection against most intracellular pathogens, they are not required to control chlamydial infections. Interestingly, Igietseme et al. (93) showed that clones of CD8⁺ T cells, likely by producing gamma interferon (IFN- γ), enhance clearance of a *C. muridarum* genital infection, and Nogueira et al. (94) demonstrated that cross-mucosa protection (respiratory and genital) is mediated by CD4⁺ and CD8⁺ T cells and not by antibodies.

After vaccination, some of the circulating Th1 lymphocytes may become mucosal tissue-resident memory cells (Trm) rapidly reducing *C. muridarum* load upon reinfection (85, 95). This hypothesis is consistent with the detection of CD4⁺ T cells in the mouse genital tract tissues long after the infection was cleared (96). Once these lymphocytes have been deposited locally, they may protect against microbial invasion by both antigen-specific and -nonspecific means and even undergo autonomous proliferation (97–99). Thus, as first proposed by Morrison and Morrison (96), an effective *C. trachomatis* vaccine may need to induce Trm in the genital tract mucosa (95).

The role of B cells and/or antibodies against a primary infection is not clear. However, antibodies have been found to be as protective against reinfection as CD4⁺ T cells, making them important in vaccine development (90, 100–102). Following a primary *C. muridarum* infection of the genital tract, mice are resistant to a rechallenge if CD4⁺ T cells and/or antibodies are present (100, 103, 104). Antibody-deficient mice and those that lack Fc receptors resolve a primary *C. muridarum* genital infection, but not a secondary infection, as well as WT animals do (44, 64, 90, 100).

Considering the extraordinary complexity of the antibody response, it is not surprising that in humans and animal models, some antibodies have been found to be protective, while others correlated with pathogenesis. For example, high levels of antibodies to the *C. trachomatis* 60-kDa heat shock protein (Hsp60) have more often been detected in patients with long-term sequelae than in individuals without complications (105–107). However, high IgA levels in the genital tract protect mice against a *C. muridarum* infection and correlate with protection against the long-term sequelae (108, 109). In humans, mucosal antibodies, especially IgA, correlate with reduced bacterial shedding (108). Also, even in the absence of T cells, passive immunization of mice with monoclonal antibodies can control a primary *C. muridarum* infection (110, 111).

Th1 cytokines, particularly IFN- γ and interleukin 12 (IL-12), are needed for protection against *C. muridarum* (112, 113). In contrast, IL-10, a Th2 cytokine, was found to be associated with pathological responses (114). The critical role of IFN- γ against chlamydial infections has been demonstrated using neutralizing antibodies and by showing that mice deficient in IFN- γ or its receptor do not resolve a primary *C. muridarum* genital infection (112, 115). These animals develop systemic dissemination but are partially protected against reinfection (101, 113, 116). In conclusion, based on the evidence we have in mice infected with *C. muridarum*, to elicit optimal protection, a chlamydial vaccine will have to induce CD4⁺ T cells with Th1-biased cytokines, in particular IFN- γ , and humoral responses, especially mucosal antibodies.

C. TRACHOMATIS VACCINE ANTIGENS

Whole-cell vaccines. In mice, intranasal immunization with live elementary bodies (EB) was the first approach shown to elicit very robust protection against a *C. muridarum* genital infection (117, 118). Following an intrabursal challenge, vaccinated mice showed a significant decrease in vaginal shedding and, more importantly, protection against infertility. This protection was found to be long-lived and also protected newborn mice, suggesting that a live-chlamydia vaccine could be effective in very young individuals before sexual maturity (119, 120). As determined by vaginal shedding, intranasal inoculation with live EB was also found to protect mice against a vaginal challenge with *C. trachomatis* serovar E (Bour) (121). Protection with *C. muridarum* UV-inactivated EB was not as effective as that obtained with viable organisms,

and reticulate bodies were not protective (121–124). UV-inactivated serovar E (Bour) EB, with AS01B as an adjuvant, were shown to induce cross protection against vaginal and intrauterine challenges with serovar K (UW-31/Cx) as determined by shedding (125). Adoptive transfer of dendritic cells pulsed *ex vivo* with inactivated *C. muridarum* EB achieved very strong protection that was considered to depend on IL-12 production by the pulsed dendritic cells (126, 127). These results support further investigation on testing nonviable whole *Chlamydia* organisms as vaccines.

The use of a live attenuated EB vaccine is another potential approach. Mice inoculated vaginally with a plasmid-cured isolate of *C. muridarum* developed an infection with a course similar to that following inoculation with the WT isolate, but no upper genital pathology was observed (128, 129). Following a subsequent challenge with the WT isolate, animals first infected with plasmid-cured *C. muridarum* had less upper genital pathology than those first inoculated with the WT. However, there was minimal protection against vaginal shedding, and the fertility of the mice was not tested. Similar findings were reported when plasmid-cured *C. muridarum* was inoculated into the ovarian bursa (129). Mice vaccinated with a plasmid-cured *C. trachomatis* serovar L2R had reduced shedding but no upper genital tract protection against a challenge with serovar D (UW-3Cx) (130).

Studies of nonhuman primates have also shown that vaccination with plasmid-cured *C. trachomatis* serovar A, at least in animals that shared a common MHC-II class allele, can induce protection against ocular infection and disease (131). However, additional work is required before this approach is tested in humans. For example, Qu et al. (132) showed that cervical inoculation of rhesus macaques with WT or plasmid-deficient *C. trachomatis* serovar D (UW-3Cx) resulted in the same levels of infection, immunity, and pathology in the genital tract. This suggests that the plasmid is not required for *C. trachomatis* to colonize the genital tracts of rhesus macaques. However, the plasmid appears to be important for *C. trachomatis* infection of the human genital tract, since most human isolates are plasmid competent (133, 134).

It is not clear why live *Chlamydia* induced better protective immunity than killed organisms (122–124). Replication and dissemination of live *Chlamydia* will broaden and expand the antigenic load (135). Also, one distinguishing feature is that inactivated organisms load far fewer peptides onto dendritic cell MHC-II molecules than do viable organisms (123). However, it will be worth comparing the levels and types of Trm in the genital tracts of mice immunized with live or dead EB, since it was recently demonstrated that the requirement for viability to induce protective immunity could be overcome by using adjuvanted nanoparticles, which correlated with the induction of transmucosal Trm (85).

Subunit vaccines. (i) Introduction. Safety concerns about the negative effects observed during the trachoma vaccine trials and costs of production have encouraged the formulation of a *C. trachomatis* subunit vaccine. Based on the trachoma vaccine trials, protection against an ocular challenge was found to be serovar/serogroup specific, an observation supported in experiments with mice (1, 2, 136, 137). DNA sequencing of the major outer membrane protein (MOMP) and computational analysis established that MOMP was likely responsible for the protection observed during the trachoma vaccine trials (137–140). Initial attempts to vaccinate animals with *C. muridarum* recombinant MOMP (rMOMP), peptides corresponding to the variable domains (VD), or with DNA plasmids that expressed this protein were not encouraging (65, 141–145). In addition, the expected serovar/serogroup specificity of the protection elicited with MOMP was, and still is, a significant concern. For these reasons, the search for additional protective antigens was undertaken. Initially, an empirical approach was used, and several proteins, particularly those localized to the outer membrane of *Chlamydia*, were tested. Since the availability of the *Chlamydia* genome sequence and implementation of protein microarrays, it became possible to identify chlamydial antigens that can induce antibody- and/or cell-mediated immune responses in infected individuals (107, 146–158). Identification of immunogenic components using these

approaches, however, does not imply that they will be protective. Therefore, it is necessary to test these antigens in animal models to demonstrate their protective ability.

(ii) Major outer membrane protein. The major outer membrane protein (MOMP) is a 40-kDa protein that accounts for approximately 60% of the mass of the outer membrane of *Chlamydia* (159, 160). Structurally, MOMP has four VD, which define the uniqueness of each serovar, alternating with five constant domains (CD) (138, 139). Like porins from other Gram-negative bacteria, MOMP has a trimeric structure (161). However, unlike most bacterial membrane proteins, MOMP is highly disulfide cross-linked with other cysteine-rich proteins, forming an intermolecular network that may account for the structural rigidity of the outer membrane of EB, since *Chlamydia* has limited amounts of peptidoglycan (162–165). In humans and animals, MOMP is an immunodominant antigen that has multiple T-cell and B-cell epitopes and can induce T-cell immunity and neutralizing antibodies (166–170).

The first evidence that a subunit *Chlamydia* vaccine could protect mice against a genital challenge was reported in 1997 (171). Mice immunized using a detergent-extracted chlamydial outer membrane complex (COMC) and incomplete Freund's adjuvant were protected as determined by the numbers of *C. muridarum* IFU recovered and fertility rates (171). This study also showed that MOMP, extracted with several detergents, was not as protective as the COMC. The authors postulated that the enhanced protection elicited by the COMC was due to the conservation of the native conformation of MOMP and not due to the additional antigens present in the COMC. In 2001, mice vaccinated with MOMP in its native trimeric conformation (nMOMP) with Freund's adjuvant were significantly protected against shedding and infertility, while those vaccinated with denatured nMOMP were not, supporting the critical role of the structure of MOMP in protection (172). The humoral immune responses were lower, but the cell-mediated immune responses were higher, in mice immunized with nMOMP versus denatured nMOMP. Pal et al. (169, 173) vaccinated mice with nMOMP, using CpG plus Montanide ISA 720 as adjuvants, and showed very robust protection against an intrabursal challenge with *C. muridarum*. Animals immunized with nMOMP were as protected against shedding and infertility as those immunized intranasally with live EB. The importance of the conformation of MOMP for protection was further demonstrated when rMOMP and nMOMP were directly compared, using CpG plus Montanide ISA 720 as adjuvants, for their ability to elicit protection against a respiratory *C. muridarum* challenge in mice (174). Based on changes in body weight, lung weight, and number of IFU recovered from the lungs, nMOMP was significantly more protective than rMOMP was. These results have now been confirmed in the genital challenge model (103, 175, 176). Vaccination with nMOMP can protect mice against intrabursal and intravaginal challenges, with significant decreases in the number of mice that have positive vaginal cultures, the number of IFU recovered, length of shedding, and infertility rates. In the vaginal model, it was shown that nMOMP-induced protection requires both CD4⁺ T cells and antibodies (103). Importantly, vaccination of nonhuman primates with the *C. trachomatis* serovar A (A2497) nMOMP, formulated with CpG-2395 and Montanide ISA 720, protected against an ocular challenge with the same serovar, as shown by a significant decrease in shedding (177). However, no protection against inflammatory responses was observed.

Immunization with *C. muridarum* rMOMP using various adjuvants has shown promising results in animal models (174, 176, 178, 179). For example, Hansen et al. (178) immunized mice with rMOMP and the cationic liposome 1 (CAF01) and, as determined by a reduced chlamydial load, obtained protection against a vaginal challenge, but hydrosalpinx formation was not prevented. Hickey et al. (179) administered rMOMP orally with a novel lipid-based adjuvant, resulting in significant protection against vaginal shedding, although *C. muridarum* was still present on the last culture day (18 days postinfection). No difference in the inflammatory response in the genital tract was noticed at 28 days postinfection. The authors proposed that the lack of protection

against tissue pathology in the rMOMP-immunized animals was due to the influence of the treatment with DMPA before the vaginal challenge (179). Carmichael et al. (176), using *C. muridarum* rMOMP, CpG plus Montanide ISA 720 as adjuvants and a combination of mucosal and systemic routes for immunization, showed for the first time protection against vaginal shedding and infertility using a recombinant antigen. Badamchi-Zadeh et al. (180) constructed a consensus MOMP from variant sequences of *C. trachomatis* serovar E. The consensus MOMP transgene was delivered using plasmid DNA, human adenovirus 5 (HuAd5) and/or modified vaccinia Ankara (MVA). The DNA-HuAd5-MVA-protein regimen was used to immunize BALB/c and B6C351 mice. Based on vaginal shedding, minimal protection against an intravaginal challenge with serovar D (UW-3/Cx) was observed.

Olsen et al. (181) recently tested a multivalent vaccine containing the VD4 and surrounding CD of MOMP from *C. trachomatis* serovars D, E, and F. This construct, adjuvanted with CAF01, elicited immune responses in mice; some of the immune responses were serovar specific, while other responses were to the conserved VD4 epitope (LNPTIAG) and neutralized serovars D, E, and F *in vitro*. Vaginally challenged mice were protected as determined by the number of *C. trachomatis* serovar D (UW-3/Cx) IFU recovered from the vagina and prevention of the inflammatory response in the upper genital tract. T-cell depletion and passive transfer of serum experiments provided evidence of the critical role of CD4⁺ T cells and antibodies in protection. Using the same MOMP construct, plus CT043 and CT414 antigens, investigators from the same laboratory elicited neutralizing antibodies and weak protection against vaginal shedding in minipigs challenged with serovar D (182). Hadad et al. (76) have reported that a construct consisting of the VD2/VD4 regions of *C. trachomatis* serovar E, adjuvanted with cholera toxin (CT), protected mice against a vaginal challenge with a clinical serovar D isolate. The authors observed a decrease in vaginal shedding during the first 2 weeks after the challenge and partial protection against infertility.

(iii) Polymorphic membrane proteins. Genome sequencing uncovered the presence of a family of polymorphic membrane proteins (Pmps) unique to *Chlamydiales* (138). In *C. trachomatis* and *C. muridarum*, there are nine *pmp* genes, and based on the presence of a C-terminal phenylalanine and a peptide leader sequence and the results of proteomic studies, these proteins were predicted to be located in the outer membrane (183–185). Pmps have molecular masses ranging from ~100 to 150 kDa, contain β -barrel domains in the C terminus, and exhibit motifs that have been associated with adhesion to the host cells in their N-terminal regions (186). On the basis of their structure, they are considered to be type V secretion autotransporters, which mediate the translocation of the N terminus to the bacterial surface. In addition, some of these proteins contain poly(G) tracts that control the phase-variable expression of the genes, providing a means by which organisms can evade host immune responses (187). Pmps have been found to be immunogenic in humans, nonhuman primates, and mice infected with *C. trachomatis* or *C. muridarum* (151, 153, 156, 188, 189). Antibodies to PmpA have been associated with decreases in fertility and live births (190).

In 2006, Crane et al. (191) reported that antibodies to PmpD could neutralize all the *C. trachomatis* serovars *in vitro*. Paes et al. (192) vaccinated mice with PmpD from *C. trachomatis* serovar E (Bour), using a synthetic agonist to TLR4 as adjuvant, and based on vaginal shedding, observed protection against a challenge with serovar D (UW-3/Cx). In 2008, Karunakaran et al. (193) using an immunoproteomic approach discovered novel T-cell epitopes in several *C. muridarum* Pmps (serovars E, F, G, and H). Vaccination of C57BL/6, BALB/c, and C3H/HeN mice with N-terminal fragments from each of these four proteins was shown to confer protection against a vaginal challenge as determined by accelerated clearance of *C. muridarum*. In particular, PmpG elicited the best protection. A polyvalent recombinant vaccine, consisting of the four Pmps from serovar D and MOMP from serovars D, F, and J, formulated with the Th1-polarizing adjuvant dimethyldioctadecylammonium (DDA)-monophosphoryl lipid A (MPL), as determined by vaginal shedding, protected C57BL/6 mice against a transcervical challenge with *C.*

trachomatis serovar D (86). Interestingly, Inic-Kanada et al. (194) found that PmpC from *C. trachomatis* serovar E elicited limited protection against an ocular challenge with *Chlamydia caviae* in guinea pigs.

(iv) Chlamydial protease-like activity factor. Chlamydial protease-like activity factor (CPAF) is a secreted protease highly conserved among all the *Chlamydia* species (99% amino acid identity among the *C. trachomatis* serovars). CPAF is produced as a zymogen and as an internal segment and inhibits proteolytic activity (195). Following dimerization and trans-autocatalytic cleavage, active CPAF behaves as a serine protease consisting of a homodimer of catalytic domains, each with two distinct subunits (196). Once in the host cell cytosol and/or released extracellularly, CPAF may act as a virulence factor by degrading eukaryotic proteins that potentially affect chlamydial colonization (197–201).

CPAF has been found to be a dominant antigen in *Chlamydia*-seropositive humans and mice (107, 151). Vaccination of mice with *C. muridarum* CPAF, using IL-12 or CpG as an adjuvant, shortens the duration of infection, decreases oviduct pathology, and elicits cross-serovar protection (202, 203). No protection against infertility was obtained following a primary *C. muridarum* vaginal challenge, but it was observed against a secondary challenge (204). The protection against vaginal shedding elicited by CPAF starts 1 to 2 weeks postchallenge. The delay may be because activated secreted CPAF is detected only after 24 h postinfection. A T-cell epitope from *C. muridarum* CPAF has been found to be protective in HLA-DR4 transgenic mice, suggesting that this antigen may be protective in humans (205). The protection elicited by CPAF is conformation independent, since both the active and inactive forms of the protein elicit the same levels of protection, and protection is mainly dependent on CD4⁺ T cells, producing IFN- γ , with contribution from CD8⁺ T cells and antibodies (124, 206, 207).

(v) Plasmid glycoprotein 3. Most *C. trachomatis* isolates have a plasmid that codes for eight proteins, including plasmid glycoprotein 3 (Pgp3) (molecular mass of 28 kDa) (134, 208, 209). Crystallization of this protein from *C. trachomatis* serovar D showed it to be an ~84-kDa homotrimer (210). Pgp3 was found in the chlamydial envelope and also in the cytoplasm of the host cell (211, 212). This protein appears to be the major virulence factor encoded in the chlamydial plasmid. Pgp3-deficient *C. trachomatis* and *C. muridarum* were highly attenuated, and this protein may promote chlamydial colonization by neutralizing host immune effectors (129, 213). However, the precise mechanism by which this protein promotes chlamydial pathogenicity remains unclear. Sera from humans and mice identified the homotrimer but not the monomer as an immunodominant antigen (151, 214). Donati et al. (215) vaccinated C3H/HeN mice with a DNA plasmid expressing *C. trachomatis* serovar D Pgp3 and a control group with the same plasmid containing an irrelevant insert. As determined by the number of positive salpinx cultures, mice vaccinated with the Pgp3 plasmid were partially protected against a genital challenge with *C. trachomatis* serovar D. Vaccination of mice with *C. muridarum* Pgp3, using CpG as an adjuvant, elicited protection against a genital challenge (216). Although the role of the plasmid in chlamydial pathogenesis is still not fully elucidated, the possibility that some of the plasmid gene-encoded proteins may be pathogenic casts doubts about their use as a vaccine. In addition, although relatively rare, plasmidless or with variant plasmids, *C. trachomatis* has been isolated from humans that may not be protected by vaccines using only plasmid antigens such as Pgp3 (134, 208, 217).

Multivalent vaccines. Antigens formulated in a multivalent vaccine may have synergistic, additive, neutral, or antagonistic effects (155, 218, 219). Several *C. muridarum* antigen combinations have been tested in the mouse model. For example, Finco et al. (155) identified chlamydial antigens that elicited humoral and cell-mediated immune responses, and combinations of these proteins were tested for their ability to protect mice against an intranasal *C. muridarum* challenge. Mice immunized with TC0106, TC0210, TC0313, or TC0741, adjuvanted with LTK63 plus CpG, had a 0.5 to 0.9 log₁₀ reduction in the number of IFU recovered from the lungs. Two four-antigen

combinations (one combination was TC0106, TC0210, TC0313, and TC0741, and the other combination was TC0106, TC0431, TC0551, and TC0890) were also tested. The first antigen combination resulted in a 4.1 log₁₀ reduction and the second antigen combination resulted in a 2.2 log₁₀ reduction in the yield of *C. muridarum* from the lungs, indicative of additive effects. Yu et al. (219) also found additive effects in the genital model. Three *C. muridarum* proteins, PmpE/F, PmpG, and MOMP, and a combination of these proteins were formulated with three different adjuvants, CpG, Abisco, and CAF01, and used to immunize mice. The combination of the three proteins, adjuvanted with CAF01, as determined by vaginal shedding, exhibited the greatest degree of protection against a genital challenge. C57BL/6, BALB/c, and C3H/HeN mice immunized with a multisubunit recombinant vaccine that included PmpE, PmpF, PmpG, PmpH, and MOMP, and DDA-MPL as the adjuvant, also conferred better protection against a genital challenge than immunization with single antigens (220). Coler et al. (125) also showed that MOMP combined with CT875 and adjuvanted with AS01B elicited better protection against a vaginal challenge with *C. trachomatis* serovar K (UW-31/Cx) than the individual antigens.

Neutral effects by combining *C. muridarum* antigens have also been reported. Yu et al. (221) vaccinated mice with PmpE, PmpF, PmpG, Aasf, RplF, TC0420, or TC0825, adjuvanted with DDA-MPL, and challenged the animals in the genital tract. PmpG elicited the most robust immune response and the best protection as shown by a decrease in the number of IFU recovered. However, three combinations of antigens (PmpE-PmpF-PmpG-PmpH-Tarp, Aasf-RplF-Rec0, and TC0420-TC0825-TC0285) only protected as well as the best individual protein in the formulation. Similar neutral findings were reported when testing combinations of antigens in the respiratory model (222). Mice were immunized with components of the *C. muridarum* putative ATP synthase complex TC0580, TC0581, TC0582, and TC0584 or with MOMP. In addition, TC0582 was formulated in combination with TC0580, TC0581, or MOMP. Animals immunized with combinations of two of these three antigens were protected only as well as mice vaccinated with MOMP, the most protective protein in the formulation. Also, Li et al. (203) reported that the addition of CPAF to MOMP, or IncA, from *C. trachomatis* serovar D (UW3-Cx) did not enhance the CPAF-induced effect on *C. muridarum* clearance or oviduct pathology. On the basis of these results, when formulating a multivalent subunit chlamydial vaccine, it will be necessary to evaluate the interactions between the antigens before implementation.

Other potential vaccine antigen candidates. In addition to the above-discussed antigens, other chlamydial proteins have been tested for their ability to induce immune responses and/or protection against infection and/or disease. Several excellent reviews have discussed these findings (45–47, 223–228). Some of the antigens that have been found to elicit protection in the mouse model include the outer membrane protein B (OmcB), putative type III secretion effector protein Tarp, macrophage infectivity potentiator (MIP), CopB, CopD, Cap1, and CT584, the inclusion membrane protein (IncA), porin protein B (PorB), the ribonucleoside reductase (NrdB), and glycogen phosphorylase (229–238). The ability of these antigens to induce robust protective immune responses is limited and requires additional testing.

ADJUVANTS

Most of the current vaccines against microbial pathogens are formulated using live attenuated or whole inactivated organisms (239, 240). Since the discovery of Toll-like receptors (TLRs), it has become clear that microbes contain not only antigenic components but also other products that, by activating these eukaryotic cell receptors, have an adjuvant effect and help stimulate robust and well-defined innate and adaptive host immune responses. According to C. A. Janeway, this mechanism explained the efficacy of whole-cell vaccines: “the immunologist’s dirty little secret” (241–245). Thus, when the vaccinated host is exposed to a pathogen, rapid and focused immune responses occur.

The implementation of subunit vaccines, like those for hepatitis B virus (HBV) and human papillomavirus (HPV), has required the inclusion of several adjuvants in their

formulation to replicate the robust immunological responses elicited by whole-organism vaccines (239, 240, 246, 247). Because individual adjuvants are only moderately effective at eliciting broad long-lasting protective immune responses and are often targeted to a single type of TLR, there is a need to use several adjuvants for subunit vaccines. In addition, the distribution of TLRs varies among tissues and thus the need to test adjuvant combinations against pathogens, such as *C. trachomatis*, that have multiple portals of entry.

The bacterial components with TLR immune adjuvant activity are called pathogen-associated molecular patterns (PAMPs) (248–254). Examples of PAMPs include membrane components, i.e., lipopolysaccharide (LPS), flagellin, lipoteichoic acid, porins, and intracellular components, such as nucleic acids (241, 243). Following a primary infection, some pathogens elicit solid protective immune responses. For these responses, we can assume that the native antigens and PAMPs present in the organisms are inducing innate and adaptive immune responses that protect the host against reinfection (239, 240, 248–254). However, many bacterial, parasitic, and viral primary infections do not elicit robust protection against a secondary infection. Therefore, against these pathogens, including *Chlamydia*, it may be necessary to formulate vaccines that elicit “unnatural immunity” (255). During a *Chlamydia* infection, TLR- and nucleotide-binding oligomerization domain 1 (NOD1)-mediated activation occurs (256–258). Several chlamydial PAMPs, including LPS, MOMP, macrophage infectivity potentiator (MIP), and heat shock protein 60 (Hsp60), are involved in this process, resulting in signaling mainly through TLR2 and TLR4 (257, 259–262). However, all these chlamydial PAMPs, including LPS, induce weak immune responses, and this may explain the lack of robust protection elicited by a primary infection (262).

Initial chlamydial vaccine trials were performed using alum and oil in water adjuvants, now known to be Th2-biased adjuvants. When it was found that, at least in the mouse model, Th1-biased immune responses were necessary to induce protection, new adjuvants were tested. Several studies have used single adjuvants and adjuvant combinations in vaccine formulations to protect mice against a *C. muridarum* challenge.

To determine the relative efficacy of single adjuvants, the following nine ligands to TLR or NOD receptors were screened for their ability to protect against a *C. muridarum* respiratory infection: Pam₂CSK₄ (TLR2/6), poly(I:C) (TLR3), monophosphoryl lipid A (MPL) (TLR4), *Bacillus subtilis* flagellin (TLR5), imiquimod R837 (TLR7), imidazoquinoline R848 (TLR7/8), CpG-1826 (TLR9), M-Tri-DAP (InvivoGen) (NOD1/2), and muramyl dipeptide (NOD2) (263). Mice were vaccinated with rMOMP, adjuvanted with each individual agonist, and challenged intranasally, and protection was determined based on changes in the weight of the body and lungs and the number of IFU recovered from the lungs. On the basis of these parameters, the most efficacious adjuvants were Pam₂CSK₄ and poly(I:C). CpG-1826 elicited intermediate protection, while monophosphoryl lipid A induced minimal protection (263). Based on the IgG2a/IgG1 ratio in serum, Pam₂CSK₄ and MPL elicited Th2-biased immune responses, while CpG-1826 induced strong Th1 responses and poly(I:C) induced balanced Th1/Th2 responses. The lack of correlation between Th1/Th2 responses, as determined by the IgG2a/IgG1 ratio, and protection suggests that, by itself, this may not be an adequate immunological parameter to predict protection. CPAF formulated with CpG-1826 or recombinant murine IL-12, as single adjuvants, elicited similar Th1 immune responses and limited protection against a genital challenge (124, 203, 264, 265).

Several studies have characterized the use of adjuvant combinations to protect against *C. muridarum* infections. For example, Yu et al. (219) formulated recombinant PmpG-1, PmpE/F-2, and MOMP individually or in combination with three different adjuvants, CpG-1826, AbiSco-100 or CAF01. The combination of PmpG-1, PmpE/F-2, and MOMP plus CAF01, as determined by *C. muridarum* shedding, was the most efficacious to protect C57BL/6 and BALB/c mice against a vaginal challenge. The CpG-1826 formulation failed to protect, supporting the need for the use of adjuvant combinations. This group of investigators confirmed those results by testing four combinations of adjuvants, DDA-MPL, CAF01, CAF04, and Montanide ISA 720 VG plus

CpG-1826, in addition to alum. PmpG was used as the test antigen. The most robust immune responses and best protection against vaginal shedding were observed when DDA-MPL or CAF01 was utilized as the adjuvant (221). These two adjuvant combinations elicited the highest frequency of multifunctional CD4 T cells coexpressing IFN- γ and tumor necrosis factor alpha (TNF- α), supporting the role of these cytokines in protection.

Adjuvant combinations have also been tested using MOMP as the antigen. In the genital model, the combination of CpG-1826 plus Montanide ISA 720 VG, a non-Toll receptor adjuvant, has been found to be quite effective at eliciting protective immune responses, using both nMOMP and rMOMP as antigens (169, 176, 266). MF59, a detergent-stabilized oil-in-water emulsion containing squalene and currently in human use, was found to elicit better protection against a genital *C. muridarum* challenge in mice than when single adjuvants, LT-K63 or LT-RT2, derived from *Escherichia coli* enterotoxin, were formulated with nMOMP (267). Cheng et al. (268) compared combinations of CpG-1826 with Pam₂CSK₄ or with Montanide ISA 720 VG. The Pam₂CSK₄ plus CpG-1826 combination was found to elicit the most robust protection against a *C. muridarum* respiratory challenge (268). IC31 is an adjuvant that combines the oligodeoxynucleotide d(IC)₁₃ (ODN1a) with the peptide KLKLLLLLKLK (KLK) (269). IC31 generates a depot at the injection site and provides immune stimulation via the TLR9/MyD88 pathway (270–272). This adjuvant combination formulated with nMOMP elicited significant protection against a respiratory challenge with *C. muridarum* (273).

ROUTES OF IMMUNIZATION AND DELIVERY SYSTEMS

The utilization of a mucosal route for immunization appears to be relevant for protection against mucosal pathogens such as *C. trachomatis*. Mucosal tissues comprise the largest source of immunity in the body and are the first line of defense against many pathogens (274–280). The genital tract is considered to be a component of the common mucosal immune system (CMIS). It is assumed that stimulation of the CMIS results in immune responses at remote mucosal effector sites, but stimulation of the various mucosal inductive sites results in uneven distribution of immune responses at the effector sites. Overall, the most effective way to induce immune responses at a specific effector site is to locally administer the vaccine or, perhaps, stimulate sites with related lymph drainages (117, 176, 279, 281–283).

In addition to eliciting a solid immune response at the entry site, deciding what route to use for vaccination requires evaluation of other factors, including safety, ease of use, cost, societal acceptance, and adjuvant availability. Immunization by the intravaginal route seems the most appropriate choice for eliciting protection against genital pathogens. Intravaginal immunization through use of a gel has been successful against cholera, and both intravaginal and rectal immunizations have been utilized against HIV (239, 240, 284–287). The main limitation of this route is patient acceptance. Furthermore, low levels of IgA and IgG in vaginal fluid after vaginal vaccination alone have been reported (279, 281). Oral immunization is readily acceptable (286). A good example is the live-poliovirus vaccine. Yet, for subunit vaccines, the need for a successful delivery system and the large amounts of antigen required for robust immune responses severely limit this approach. The sublingual route may be a more desirable alternative and has been successful in mouse models (176, 283, 288). Colonic immunization may also be a possibility, since it has been shown to induce higher vaginal and serum IgA levels than oral and intramuscular immunizations (176, 289). The ease of use and patient acceptance will have to be improved by utilizing oral delivery systems. The intranasal route induces mucosal IgA and stimulates immunity not only in local tissues but also in the genital tract (117, 290, 291). Unfortunately, intranasal immunization may negatively affect the central nervous system, and this safety issue is why some vaccines have been pulled from the market (287, 292).

Systemic (intramuscular and subcutaneous) and mucosal (sublingual and colonic) routes, alone and in combination, were tested by Ralli-Jain et al. (283) for their ability to protect mice against a *C. muridarum* respiratory challenge. The best protection was achieved when mucosal, followed by systemic, immunizations were utilized. Carmichael

et al. (176) also tested combinations of mucosal (intravaginal, colonic, and intranasal) and systemic (intramuscular and subcutaneous) routes to immunize mice against a vaginal challenge with *C. muridarum*. The strongest *Chlamydia*-specific humoral and cell-mediated immune responses were obtained in the groups immunized by a combination of mucosal and systemic routes. As determined by vaginal shedding and fertility rates, animals vaccinated by a combination of mucosal and systemic routes were also the best protected. Mucosal immunization by itself elicited weak immune responses and minimal protection.

Work by Stary et al. (85) supports enhanced protection using a mucosal route for immunization. These authors vaccinated mice with UV-inactivated *C. trachomatis* serovar D (UW-3/Cx) EB by the intranasal or intrauterine route using nanoparticles coupled to R848. Mucosal immunization elicited Trm that migrated to the uterine mucosa, eliciting protection against a transcervical challenge, while subcutaneous immunization failed to induce Trm and protect.

Several delivery systems, including DNA plasmids, poliovirus, adenovirus, hepatitis B virus, influenza virus, *Vibrio cholerae* ghosts, and nanoparticles, have been used to vaccinate mice with various chlamydial antigens (65, 141, 144, 293–300). Although some of these delivery systems offer interesting opportunities, such as the ability to carry antigens from several pathogens, so far the results obtained do not appear to offer significant advantages over well-established approaches. Furthermore, including antigens that are not medically relevant from the delivery system in a vaccine introduces unknown safety issues and may divert immune responses. The use of edible plants is certainly an interesting approach but needs to be carefully evaluated for its possible negative impact (301). Therefore, more work is needed before any of these delivery systems is implemented.

CROSS-SEROVAR PROTECTION

The low virulence of *C. trachomatis* in mice and the lack of *C. muridarum* serovars present a major challenge for testing cross-serovar protection in the mouse model. However, several investigators have addressed this problem. For example, Tuffrey et al. (302) used a recombinant fragment of *C. trachomatis* serovar L1 MOMP to immunize mice and challenged them by the vaginal or uterine route with serovar F (NI1). In some groups of vaccinated mice, there was a reduction in the duration of colonization and the severity of salpingitis. Li et al. (203) constructed a multivalent vaccine that included three recombinant proteins, CPAF, MOMP, and IncA, from serovar D. Vaccinated mice were challenged vaginally with *C. muridarum*. Immunized mice had less shedding and upper genital tract pathology than the negative-control animals did. Eko et al. (303) immunized mice with *V. cholerae* ghosts expressing PorB and/or PmpD from serovar D and challenged them vaginally with *C. muridarum*. The groups vaccinated with one or both antigens had a significant decrease in vaginal shedding. A different approach was taken by Olivares-Zabaleta et al. (130). Mice were vaccinated intravaginally with the plasmid-free *C. trachomatis* serovar L2 (25667R) and subsequently challenged vaginally with serovar D (UW-3/Cx). Immunized mice were not protected against infection or inflammatory disease but had a reduced infectious burden. By taking advantage of the respiratory model, Tifrea et al. (304) showed that mice immunized with *C. trachomatis* recombinant MOMP from serovars D (UW-3/Cx), E (Bour), and F (IC-Cal-3) can be protected against disease and bacterial burden from a challenge with *C. muridarum*. In conclusion, although we do not have a good mouse model, these results suggest that by using a multivalent vaccine, it may be possible to elicit solid cross-serovar protective responses.

CAN THE IMMUNOLOGICAL AND PROTECTION FINDINGS IN MICE BE DIRECTLY TRANSLATED TO HUMANS?

In evolutionary terms, differences in innate and adaptive immune responses between humans and mice have developed over the last 100 million years when primates and rodents were separating (305–307). Living in contrasting habitats and being exposed to different microorganisms have resulted in significant divergence of their

immune systems (308–313). In the last 100 years, the establishment of inbred strains of mice has added another layer of immunological differences (314). As a result, we cannot be certain that the findings obtained in the mouse model will be directly applicable to humans. Even more, results in one strain of mice may not directly extrapolate to another strain. Here, we will briefly discuss some differences between the innate and adaptive immune systems of humans and mice that may impact the development and implementation of a *C. trachomatis* vaccine.

One of the main defense mechanisms against pathogens in humans and mice is the presence of pattern recognition receptors (PRR), such as the TLRs (10 present in humans and 13 in mice) that activate the innate immune system by binding molecular patterns of microorganisms, such as LPS (312, 313, 315, 316). In humans, binding of ligands to TLRs causes significant inflammatory responses that help protect against pathogens by limiting their burden. In contrast, mice respond very weakly to TLR agonists. For example, in humans, a dose of $\sim 15 \mu\text{g}$ of LPS/kg of body weight causes severe diseases, including shock, while in mice, the 50% lethal dose (LD_{50}) is $\sim 10 \text{ mg/kg}$ (309, 317). Furthermore, significant differences are also found between different strains of inbred mice. For example, agonists of TLR3 were the most effective adjuvants to elicit IFN- γ -producing NK, CD4, and CD8 T cells in C57BL/6 mice, while in BALB/c mice, TLR7/8 was found to be the most effective (318, 319).

IFN- γ is released in humans and mice during inflammation to trigger innate immune responses. In mice, IFN- γ induces the expression of the p47 immunity-related GTPase (IRG) proteins that include proteins encoded by 18 genes, and IRG knockout mice are highly susceptible to pathogens (320). Humans express only two IRG proteins, and neither of the two proteins is induced by IFN- γ . In mice, IFN- γ induces three different IRG genes against *C. trachomatis*, which leads to rerouting of the inclusions to autophagosomes (321). In contrast, *C. muridarum* has a large toxin with homology to Yop7 that blocks the interaction of IRG proteins with the inclusion membrane (112). In addition, in human epithelial cells, IFN- γ elicits expression of indoleamine 2,3-dioxygenase, which, by depleting the host tryptophan pools, inhibits the growth of *C. muridarum*. However, *C. trachomatis* can grow by producing a tryptophan synthase that may use indole generated by microbes in the human genital tract to produce tryptophan (88, 322).

The leukocyte compositions of humans and mice are also significantly different. Humans have 50 to 70% neutrophils and 50 to 30% lymphocytes, while mice have only 10 to 30% neutrophils and 90 to 70% lymphocytes (312, 313). In addition to differences in the proportions, there are functional differences between human and mouse neutrophils. For example, human neutrophils express many defensins, while mouse neutrophils express only a few (323–325). Similarly, myeloperoxidase levels in mouse neutrophils are 80 to 90% lower than in human neutrophils (326). Significant differences also exist between human and mouse eosinophils, granulocytes, monocytes/macrophages, NK cells, and mast cells (313).

Fc receptor (FcR) represents a link between innate and adaptive immune responses. Fc α R1 (CD89) is an important IgA receptor in humans and is expressed in neutrophils, eosinophils, monocytes/macrophages, and dendritic and Kupffer cells, while mice lack Fc α R1 and use alternative receptors (310).

There are also clear differences in the adaptive immune responses between humans and mice (310). For example, IL-7 receptor (IL-7R) deficiency in mice blocks development of both B and T cells (327). In humans, however, IL-7R deficiency blocks only the development of T cells, suggesting that B-cell development is not dependent on IL-7 (328). Also, mice, but not humans, exclusively express CD5 and CD23 in B cells, while CD38 is expressed in human, but not mouse, plasma cells (329). Mice produce IgA, IgD, IgE, IgG (IgG1, IgG2a, IgG2b, and IgG3) and IgM, while humans express IgA (IgA1 and IgA2), IgD, IgE, and IgG (IgG1, IgG2, IgG3 and IgG4). Interestingly, C57BL/6, C57BL/10, SJL, and NOD mice produce IgG2c instead of IgG2a (330). In mice, IL-4 induces IgG1 and IgE, while in humans, it elicits IgG4 and IgE.

An important component of adaptive immunity is the differentiation of T cells

toward the Th1 or Th2 phenotype. Mosmann and Coffman (331) first demonstrated in mice the polarization of T cells. While Th1 and Th2 cells can be found in human diseases, the polarization is not so clear. For example, in mice, IL-10 is a Th2 cytokine, while in humans, both Th1 and Th2 cells can make IL-10 (332). Also, in humans, IFN- α is produced by several types of cells in response to viral infections inducing Th1 development by activation of STAT4. In contrast, in mice, IFN- α does not induce Th1 cells and does not activate STAT4 (333).

From this brief analysis, we can conclude that there are many differences between the immune systems of humans and mice and even between various strains of inbred mice. From the vaccinology perspective, it is likely that the antigens that are effective in mice will also be effective in humans. In particular, MOMP, already indirectly identified in the original trachoma vaccine trials as a dominant protective antigen, will likely be protective in humans. Other chlamydial antigens, such as Pmps and CAF, known to elicit humoral and cell-mediated immune responses in humans and protection in mice will also likely be protective in humans. However, an adjuvant(s) found to be the most efficacious in mice might not be the most effective in humans. To broaden the chances of success, testing adjuvants in inbred and outbred mice is recommended. Routes and delivery systems for vaccines are fairly restricted in humans. Utilizing one of the most common routes currently used for delivery of human vaccines, the intramuscular or subcutaneous route, will greatly facilitate implementation. Combining mucosal and systemic routes will likely improve *Chlamydia* vaccine efficacy, but it may pose significant safety and practical challenges.

In summary, as Gibbons and Spencer (311) concluded after reviewing human and mouse intestinal immunity: "Although the value of animal models should not be underestimated, close attention should be given to the detail; the functional outcome may seem the same but the mechanism might be different." Recent genomic studies support this conclusion (308, 309).

PROSPECTS FOR A HUMAN *C. TRACHOMATIS* VACCINE

Although great progress has been made over the last 4 decades, the prospects of implementing a *Chlamydia* vaccine against genital infections in the near future are still under discussion. *C. trachomatis* causes significant morbidity but no mortality. Therefore, the first priority for the implementation of a *C. trachomatis* vaccine is safety. Based on the findings observed during the vaccine trachoma trials, the development of a delayed-type hypersensitivity reaction and increase in susceptibility to infection, or any other negative effect, has to be avoided. The use of a live attenuated or inactivated whole-organism vaccine may be justifiable to protect against trachoma, but it is highly unlikely that it will be used against genital infections. In addition to safety issues, the costs of producing such a vaccine will be difficult to justify. Therefore, a subunit recombinant vaccine will probably be deployed.

A therapeutic *C. trachomatis* vaccine may have some efficacy if it is delivered before irreversible damage occurs in the female genital tract. Yet, a therapeutic vaccine, although possible, is highly unlikely to be implemented, since at least with our current methodologies, detection of early onset of upper genital tract pathology is a major challenge (334). In the case of trachoma, it may be worthwhile to explore the effects of a therapeutic vaccine, particularly since there is already evidence that it can be effective in humans (335–337).

It is likely that most of our current vaccines do not induce sterilizing immunity (239, 240). To block chlamydial infection, a vaccine will have to elicit high levels of mucosal/systemic protective antibodies that are maintained throughout the life of the individual, or at least their reproductive life, a goal not easily achievable. Existing vaccines control the pathogen at the site of entry and therefore minimize disease, including long-term sequelae. Additionally, they decrease shedding and therefore transmission. At the population level, this is a critical effect, since the number of newly infected individuals can rapidly decline. Using a computer model, it was determined that in the case of a *C. trachomatis* vaccine, over a period of at least 10 years, even when its efficacy was only

50%, the decline in new infections will be dramatic (338). This conclusion was supported by other studies that also determined that vaccination was cost-effective (339, 340). Vaccinating both males and females will further expedite the control of this pathogen (341).

Based on the experimental work done with single-antigen vaccines, nMOMP induces the most robust protection against shedding and infertility. Producing enough nMOMP, by direct extraction from *Chlamydia*, will be extremely expensive. In addition, due to the serovar/serogroup specificity of the protection, a vaccine may need to be formulated with MOMP from two to four serovars (45, 137, 342). As shown by Olsen et al. (181), a synthetic MOMP vaccine that includes specific epitopes from various serovars is a potentially attractive alternative. Another possibility is to formulate a multivalent vaccine with rMOMP and other well-conserved recombinant antigens, such as CPAF and/or the Pmps. Advantages of CPAF include cross-serovar protection and a lack of dependence on its native conformation for protection, which greatly facilitate production and formulation. Shortcomings include limited protection against vaginal shedding and infertility. The Pmps are large proteins (>100 kDa), and the recombinant constructs tested so far have used only N-terminal fragments, usually less than 50% of the entire protein. The N-terminal fragments of Pmps are thought to represent the surface-exposed domains. Full-size Pmps, particularly if they can be refolded into their native conformation, will likely induce robust cross-serovar protective immune responses, since they are well conserved among all the human serovars. However, phase variation expression could limit the protective ability of Pmps, especially for PmpG (187, 189). Vaccines based on Pmps will therefore require the addition of other antigens. Also, there is no evidence yet that Pmps can protect mice against infertility.

In addition to the antigens, evaluation of adjuvants, routes, and delivery systems for immunization that are not only effective but also safe and convenient is going to be critical before a *C. trachomatis* vaccine is implemented. On the basis of the findings we have in the mouse model, the adjuvants will have to elicit robust cell-mediated and humoral immune responses. The number of adjuvants currently licensed for human use is quite limited. The recent positive experience with the implementation of a highly efficacious systemic subunit vaccine to protect against HPV-induced cervical cancer is highly encouraging. HPV infects the transitional zone of the human cervix, the same area of the epithelium *C. trachomatis* infects. This observation implies that it may also be possible to formulate an efficacious *Chlamydia* vaccine that is delivered by a systemic route (intramuscular or subcutaneous) and not a mucosal route, using the appropriate adjuvants. However, in the case of HPV, humoral immune responses appear to play the major role in protection, while for *C. trachomatis*, cell-mediated and humoral immune responses will likely be required to elicit optimal protection (59, 246, 343, 344). Therefore, the adjuvants and routes of immunization for *C. trachomatis* may differ significantly from those needed for HPV.

Once a vaccine that elicits robust protection in animal models has been found, a set of criteria will need to be defined to measure protection during the human clinical trials. Having a single parameter to assess protection may not be possible. To determine whether or not protection against tubal factor infertility is achieved by vaccination is not a realistic criterion, since it will require many years and a very large number of subjects to ascertain that effect. Assessment of PID episodes in the vaccinated and control populations will likely be the most robust endpoint to evaluate the efficacy of the vaccine. As shown by Westrom et al. (30), single, not multiple, severe PID episodes are the leading cause of infertility in women.

There are other parameters that can assist in evaluating the efficacy of the vaccine. In the mouse model, there is a good correlation between vaginal shedding and development of upper genital pathology. The number of animals with positive cultures and the length and severity of vaginal shedding are parameters that could be used to evaluate the efficacy of the vaccine. With these parameters, even if we do not have specific data to determine protection against upper genital pathology in a particular

individual, we could estimate the impact on transmission rates and, therefore, control of the infection in the population (338, 340).

During the vaccination trials, noninvasive radiological techniques, such as magnetic resonance imaging (MRI), could also help to assess the development of upper genital pathology (345–347). However, in addition to the high cost, the lack of sensitivity and specificity may limit the usefulness of our current methods. Serological testing of individuals before and after vaccination, using whole-genome *Chlamydia* protein microarrays to test serum and vaginal samples, could provide supportive information (148, 151, 154, 156). Measurement of inflammatory cytokines and chemokines in cervical vaginal secretions may also assist assess vaccine efficacy (348–350). Importantly, careful short-term and long-term follow-up will be required to make sure no negative effects occur at the time of vaccination and later on when the individual is exposed to *Chlamydia*.

CONCLUDING REMARKS

Work over the last 4 decades has identified vaccine components, including antigens, adjuvants, and immunization routes, that can induce significant protection against a *C. muridarum* genital challenge in the mouse model. In our opinion, to expedite the implementation of *C. trachomatis* vaccines, the next step should be to test in parallel the most promising formulations reported by various investigators. The two or three most efficacious vaccine formulations could then be evaluated in various inbred and outbred mice and other animal models, such as the guinea pig, and, if necessary, in nonhuman primates. A cooperative international effort between vaccinologists, government agencies, and private companies could result in the implementation of a *C. trachomatis* vaccine in the next decade. Currently, a MOMP-based vaccine is in phase I clinical trials (26).

REFERENCES

- Schachter J, Dawson CR. 1978. Human chlamydial infections. PSG Publishing Company, Littleton, MA.
- Taylor HR. 2008. Trachoma: a blinding scourge from the Bronze Age to the twenty-first century, 1st ed. Haddington Press Pty Ltd, Victoria, Australia.
- Wheelhouse N, Longbottom D. 2012. Endemic and emerging chlamydial infections of animals and their zoonotic implications. *Transbound Emerg Dis* 59:283–291. <https://doi.org/10.1111/j.1865-1682.2011.01274.x>.
- Taylor HR. 2009. Doyné Lecture: trachoma, is it history? *Eye (Lond)* 23:2007–2022. <https://doi.org/10.1038/eye.2008.432>.
- Halberstaedter L, von Prowazek S. 1907. Zur Aetiologie des Trachoms. *Dtsch Med Wochenschr* 33:1285–1287. <https://doi.org/10.1055/s-0029-1188920>.
- Tang FF, Chang HL, Huang YT, Wang KC. 1957. Studies on the etiology of trachoma with special reference to isolation of the virus in chick embryo. *Chin Med J* 75:429–447.
- Tang FF, Huang YT, Chang HL, Wong KC. 1957. Isolation of trachoma virus in chick embryo. *J Hyg Epidemiol Microbiol Immunol* 1:109–120.
- Collier LH. 1961. Experiments with trachoma vaccines. Experimental system using inclusion blennorrhoea virus. *Lancet* i:795–800.
- Nicollé C, Cuenod A, Baizot L. 1913. Etude expérimentale du trachome. *Arch Inst Pasteur Tunis* 4:157–182.
- Collier LH, Blyth WA. 1966. Immunogenicity of experimental trachoma vaccines in baboons. I. Experimental methods, and preliminary tests with vaccines prepared in chick embryos and in HeLa cells. *J Hyg (Lond)* 64:513–528.
- Grayston JT, Woolridge RL, Wang S. 1962. Trachoma vaccine studies on Taiwan. *Ann N Y Acad Sci* 98:352–367.
- Grayston JT, Woolridge RL, Wang SP, Yen CH, Yang CY, Cheng KH, Chang IH. 1963. Field studies of protection from infection by experimental trachoma virus vaccine in preschool-aged children on Taiwan. *Proc Soc Exp Biol Med* 112:589–595. <https://doi.org/10.3181/00379727-112-28112>.
- Grayston JT, Wang SP, Yeh LJ, Kuo CC. 1985. Importance of reinfection in the pathogenesis of trachoma. *Rev Infect Dis* 7:717–725. <https://doi.org/10.1093/clinids/7.6.717>.
- Nichols RL, Bell SD, Jr, Murray ES, Haddad NA, Bobb AA. 1966. Studies on trachoma. V. Clinical observations in a field trial of bivalent trachoma vaccine at three dosage levels in Saudi Arabia. *Am J Trop Med Hyg* 15:639–647.
- Nichols RL, Bell SD, Jr, Haddad NA, Bobb AA. 1969. Studies on trachoma. VI. Microbiological observations in a field trial in Saudi Arabia of bivalent trachoma vaccine at three dosage levels. *Am J Trop Med Hyg* 18:723–730.
- Bietti G, Werner GH. 1967. Trachoma: prevention and treatment. Charles C Thomas, Springfield, Ill.
- Woolridge RL, Grayston JT, Chang IH, Cheng KH, Yang CY, Neave C. 1967. Field trial of a monovalent and of a bivalent mineral oil adjuvant trachoma vaccine in Taiwan school children. *Am J Ophthalmol* 63(Suppl):1645–1650. [https://doi.org/10.1016/0002-9394\(67\)94158-X](https://doi.org/10.1016/0002-9394(67)94158-X).
- Sowa S, Sowa J, Collier LH, Blyth WA. 1969. Trachoma vaccine field trials in The Gambia. *J Hyg (Lond)* 67:699–717. <https://doi.org/10.1017/S0022172400042157>.
- World Health Organization. 2003. Report of the 2nd global scientific meeting on trachoma. World Health Organization, Geneva, Switzerland.
- Kroner T. 1884. Zur Aetiologie der Ophthalmoblennorrhoea neonatorum. *Zentralbl Gynaekol* 8:643–645.
- Heymann B. 1910. Ueber die Fundorte der Powazek'schen korperchen. *Berlin Klin Wochenschr* 47:663–666.
- Guiard FP. 1897. Des urethritis non gonococciques. *Ann Mal Org Genito-Urin* 15:449–499.
- Jones BR, Collier LH, Smith CH. 1959. Isolation of virus from inclusion blennorrhoea. *Lancet* i:902–905.
- Centers for Disease Control and Prevention. 2014. Sexually transmitted disease surveillance 2013. Division of STD Prevention, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention, U.S. Department of Health and Human Services, Atlanta, GA.
- Newman L, Rowley J, Vander Hoorn S, Wijesooriya NS, Unemo M, Low N, Stevens G, Gottlieb S, Kiarie J, Temmerman M. 2015. Global estimates of the prevalence and incidence of four curable sexually transmitted infections in 2012 based on systematic review and global reporting. *PLoS One* 10:e0143304. <https://doi.org/10.1371/journal.pone.0143304>.

26. Gottlieb SL, Deal CD, Giersing B, Rees H, Bolan G, Johnston C, Timms P, Gray-Owen SD, Jerse AE, Cameron CE, Moorthy VS, Kiarie J, Broutet N. 2016. The global roadmap for advancing development of vaccines against sexually transmitted infections: update and next steps. *Vaccine* 34:2939–2947. <https://doi.org/10.1016/j.vaccine.2016.03.111>.
27. Haggerty CL, Gottlieb SL, Taylor BD, Low N, Xu F, Ness RB. 2010. Risk of sequelae after Chlamydia trachomatis genital infection in women. *J Infect Dis* 201(Suppl 2):S134–S155. <https://doi.org/10.1086/652329>.
28. Ness RB, Smith KJ, Chang CC, Schisterman EF, Bass DC. 2006. Prediction of pelvic inflammatory disease among young, single, sexually active women. *Sex Transm Dis* 33:137–142. <https://doi.org/10.1097/01.qlq.0000187205.67390.d1>.
29. Price MJ, Ades AE, Soldan K, Welton NJ, Macleod J, Simms I, DeAngelis D, Turner KM, Horner PJ. 2016. The natural history of Chlamydia trachomatis infection in women: a multi-parameter evidence synthesis. *Health Technol Assess* 20:1–250. <https://doi.org/10.3310/hta20220>.
30. Westrom L, Joesoef R, Reynolds G, Hagdu A, Thompson SE. 1992. Pelvic inflammatory disease and fertility. A cohort study of 1,844 women with laparoscopically verified disease and 657 control women with normal laparoscopic results. *Sex Transm Dis* 19:185–192.
31. Brunham RC, Gottlieb SL, Paavonen J. 2015. Pelvic inflammatory disease. *N Engl J Med* 372:2039–2048. <https://doi.org/10.1056/NEJMra1411426>.
32. Darville T, Hiltke TJ. 2010. Pathogenesis of genital tract disease due to Chlamydia trachomatis. *J Infect Dis* 201(Suppl 2):S114–S125.
33. Westrom L, Bengtsson LP, Mardh PA. 1981. Incidence, trends, and risks of ectopic pregnancy in a population of women. *Br Med J (Clin Res Ed)* 282:15–18. <https://doi.org/10.1136/bmj.282.6257.15>.
34. Westrom L. 1975. Effect of acute pelvic inflammatory disease on fertility. *Am J Obstet Gynecol* 121:707–713. [https://doi.org/10.1016/0002-9378\(75\)90477-9](https://doi.org/10.1016/0002-9378(75)90477-9).
35. Westrom L. 1995. Effect of pelvic inflammatory disease on fertility. *Venerology* 8:219–222.
36. Price MJ, Ades AE, Welton NJ, Simms I, Macleod J, Horner PJ. 2016. Proportion of pelvic inflammatory disease cases caused by Chlamydia trachomatis: consistent picture from different methods. *J Infect Dis* 214:617–624. <https://doi.org/10.1093/infdis/jiw178>.
37. Ades AE, Price MJ, Kounali D, Akande VA, Wills GS, McClure MO, Muir P, Horner PJ. 2017. Proportion of tubal factor infertility due to Chlamydia: finite mixture modeling of serum antibody titers. *Am J Epidemiol* 185:124–134. <https://doi.org/10.1093/aje/kww117>.
38. Gotz H, Lindback J, Ripa T, Arneborn M, Ramsted K, Ekdahl K. 2002. Is the increase in notifications of Chlamydia trachomatis infections in Sweden the result of changes in prevalence, sampling frequency or diagnostic methods? *Scand J Infect Dis* 34:28–34. <https://doi.org/10.1080/00365540110077001>.
39. Scholes D, Stergachis A, Heidrich FE, Andrilla H, Holmes KK, Stamm WE. 1996. Prevention of pelvic inflammatory disease by screening for cervical chlamydial infection. *N Engl J Med* 334:1362–1366. <https://doi.org/10.1056/NEJM199605233342103>.
40. Brunham RC, Pourbohloul B, Mak S, White R, Rekart ML. 2005. The unexpected impact of a Chlamydia trachomatis infection control program on susceptibility to reinfection. *J Infect Dis* 192:1836–1844. <https://doi.org/10.1086/497341>.
41. Stamm W. 2008. Chlamydia trachomatis infections of the adult, p 575–593. In Holmes KK, Sparling PF, Stamm WE, Piot P, Wasserheit JN, Corey L, Cohen MS, Watts DH (ed), *Sexually transmitted diseases*, 4th ed. McGraw-Hill Book Co., New York, NY.
42. Igiertseme JU, Black CM, Caldwell HD. 2002. Chlamydia vaccines: strategies and status. *BioDrugs* 16:19–35. <https://doi.org/10.2165/00063030-200216010-00003>.
43. de la Maza LM, Peterson EM. 2002. Vaccines for Chlamydia trachomatis infections. *Curr Opin Investig Drugs* 3:980–986.
44. Morrison RP, Caldwell HD. 2002. Immunity to murine chlamydial genital infection. *Infect Immun* 70:2741–2751. <https://doi.org/10.1128/IAI.70.6.2741-2751.2002>.
45. Farris CM, Morrison RP. 2011. Vaccination against Chlamydia genital infection utilizing the murine *C. muridarum* model. *Infect Immun* 79:986–996. <https://doi.org/10.1128/IAI.00881-10>.
46. Yu H, Karunakaran KP, Jiang X, Brunham RC. 2016. Subunit vaccines for the prevention of mucosal infection with Chlamydia trachomatis. *Expert Rev Vaccines* 15:977–988. <https://doi.org/10.1586/14760584.2016.1161510>.
47. Rockey DD, Wang J, Lei L, Zhong G. 2009. Chlamydia vaccine candidates and tools for chlamydial antigen discovery. *Expert Rev Vaccines* 8:1365–1377. <https://doi.org/10.1586/erv.09.98>.
48. Korenromp EL, Wi T, Resch S, Stover J, Broutet N. 2017. Costing of national STI program implementation for the global STI control strategy for the health sector, 2016–2021. *PLoS One* 12:e0170773. <https://doi.org/10.1371/journal.pone.0170773>.
49. Poston TB, Gottlieb SL, Darville T. 19 January 2017. Status of vaccine research and development of vaccines for Chlamydia trachomatis infection. *Vaccine* <https://doi.org/10.1016/j.vaccine.2017.01.023>.
50. Gottlieb SL, Johnston C. 2017. Future prospects for new vaccines against sexually transmitted infections. *Curr Opin Infect Dis* 30:77–86. <https://doi.org/10.1097/QCO.0000000000000343>.
51. Brunham RC, Rappuoli R. 2013. Chlamydia trachomatis control requires a vaccine. *Vaccine* 31:1892–1897. <https://doi.org/10.1016/j.vaccine.2013.01.024>.
52. Miller WC, Ford CA, Morris M, Handcock MS, Schmitz JL, Hobbs MM, Cohen MS, Harris KM, Udry JR. 2004. Prevalence of chlamydial and gonococcal infections among young adults in the United States. *JAMA* 291:2229–2236. <https://doi.org/10.1001/jama.291.18.2229>.
53. Darville T. 2006. Chlamydia trachomatis genital infection in adolescents and young adults. *Adv Exp Med Biol* 582:85–100. https://doi.org/10.1007/0-387-33026-7_8.
54. Brunham RC, Kimani J, Bwayo J, Maitha G, Maclean I, Yang C, Shen C, Roman S, Nagelkerke NJ, Cheang M, Plummer FA. 1996. The epidemiology of Chlamydia trachomatis within a sexually transmitted diseases core group. *J Infect Dis* 173:950–956. <https://doi.org/10.1093/infdis/173.4.950>.
55. Geisler WM, Lensing SY, Press CG, Hook EW, III. 2013. Spontaneous resolution of genital Chlamydia trachomatis infection in women and protection from reinfection. *J Infect Dis* 207:1850–1856. <https://doi.org/10.1093/infdis/jit094>.
56. Pal S, Peterson EM, de la Maza LM. 2001. Susceptibility of mice to vaginal infection with Chlamydia trachomatis mouse pneumonitis is dependent on the age of the animal. *Infect Immun* 69:5203–5206. <https://doi.org/10.1128/IAI.69.8.5203-5206.2001>.
57. Pal S, Hui W, Peterson EM, de la Maza LM. 1998. Factors influencing the induction of infertility in a mouse model of Chlamydia trachomatis ascending genital tract infection. *J Med Microbiol* 47:599–605. <https://doi.org/10.1099/00222615-47-7-599>.
58. Nigg C. 1942. An unidentified virus which produces pneumonia and systemic infection in mice. *Science* 95:49–50. <https://doi.org/10.1126/science.95.2454.49-a>.
59. Brunham RC, Rey-Ladino J. 2005. Immunology of Chlamydia infection: implications for a Chlamydia trachomatis vaccine. *Nat Rev Immunol* 5:149–161. <https://doi.org/10.1038/nri1551>.
60. de la Maza LM, Pal S, Khamesipour A, Peterson EM. 1994. Intravaginal inoculation of mice with the Chlamydia trachomatis mouse pneumonitis biovar results in infertility. *Infect Immun* 62:2094–2097.
61. Read TD, Brunham RC, Shen C, Gill SR, Heidelberg JF, White O, Hickey EK, Peterson J, Utterback T, Berry K, Bass S, Linher K, Weidman J, Khouri H, Craven B, Bowman C, Dodson R, Gwinn M, Nelson W, DeBoy R, Kolonay J, McClarty G, Salzberg SL, Eisen J, Fraser CM. 2000. Genome sequences of Chlamydia trachomatis MoPn and Chlamydia pneumoniae AR39. *Nucleic Acids Res* 28:1397–1406. <https://doi.org/10.1093/nar/28.6.1397>.
62. Tuffrey M, Taylor-Robinson D. 1981. Progesterone as a key factor in the development of a mouse model for genital-tract infection with Chlamydia trachomatis. *FEMS Microbiol Lett* 12:111–115. <https://doi.org/10.1111/j.1574-6968.1981.tb07622.x>.
63. Darville T, Andrews CW, Jr, Laffoon KK, Shymasani W, Kishen LR, Rank RG. 1997. Mouse strain-dependent variation in the course and outcome of chlamydial genital tract infection is associated with differences in host response. *Infect Immun* 65:3065–3073.
64. Morrison SG, Su H, Caldwell HD, Morrison RP. 2000. Immunity to murine Chlamydia trachomatis genital tract reinfection involves B cells and CD4⁺ T cells but not CD8⁺ T cells. *Infect Immun* 68:6979–6987. <https://doi.org/10.1128/IAI.68.12.6979-6987.2000>.
65. Dong-Ji Z, Yang X, Shen C, Lu H, Murdin A, Brunham RC. 2000. Priming with Chlamydia trachomatis major outer membrane protein (MOMP) DNA followed by MOMP ISCOM boosting enhances protection and is associated with increased immunoglobulin A and Th1 cellular immune responses. *Infect Immun* 68:3074–3078. <https://doi.org/10.1128/IAI.68.6.3074-3078.2000>.
66. Chen J, Zhang H, Zhou Z, Yang Z, Ding Y, Zhou Z, Zhong E, Arulanan-

- dam B, Baseman J, Zhong G. 2014. Chlamydial induction of hydrosalpinx in 11 strains of mice reveals multiple host mechanisms for preventing upper genital tract pathology. *PLoS One* 9:e95076. <https://doi.org/10.1371/journal.pone.0095076>.
67. Zhang H, Zhou Z, Chen J, Wu G, Yang Z, Zhou Z, Baseman J, Zhang J, Reddick RL, Zhong G. 2014. Lack of long-lasting hydrosalpinx in A/J mice correlates with rapid but transient chlamydial ascension and neutrophil recruitment in the oviduct following intravaginal inoculation with *Chlamydia muridarum*. *Infect Immun* 82:2688–2696. <https://doi.org/10.1128/IAI.00055-14>.
 68. Ito JI, Jr, Harrison HR, Alexander ER, Billings LJ. 1984. Establishment of genital tract infection in the CF-1 mouse by intravaginal inoculation of a human oculogenital isolate of *Chlamydia trachomatis*. *J Infect Dis* 150:577–582. <https://doi.org/10.1093/infdis/150.4.577>.
 69. Lyons JM, Morre SA, Airo-Brown LP, Pena AS, Ito JI. 2005. Comparison of multiple genital tract infections with *Chlamydia trachomatis* in different strains of female mice. *J Microbiol Immunol Infect* 38:383–393.
 70. Sturdevant GL, Kari L, Gardner DJ, Olivares-Zavaleta N, Randall LB, Whitmire WM, Carlson JH, Goheen MM, Selleck EM, Martens C, Caldwell HD. 2010. Frameshift mutations in a single novel virulence factor alter the in vivo pathogenicity of *Chlamydia trachomatis* for the female murine genital tract. *Infect Immun* 78:3660–3668. <https://doi.org/10.1128/IAI.00386-10>.
 71. Lyons JM, Morre SA, Airo-Brown LP, Pena AS, Ito JI. 2005. Acquired homotypic and heterotypic immunity against oculogenital *Chlamydia trachomatis* serovars following female genital tract infection in mice. *BMC Infect Dis* 5:105. <https://doi.org/10.1186/1471-2334-5-105>.
 72. Ito JI, Jr, Lyons JM, Airo-Brown LP. 1990. Variation in virulence among oculogenital serovars of *Chlamydia trachomatis* in experimental genital tract infection. *Infect Immun* 58:2021–2023.
 73. Sturdevant GL, Zhou B, Carlson JH, Whitmire WM, Song L, Caldwell HD. 2014. Infectivity of urogenital *Chlamydia trachomatis* plasmid-deficient, CT135-null, and double-deficient strains in female mice. *Pathog Dis* 71:90–92. <https://doi.org/10.1111/2049-632X.12121>.
 74. Ramsey KH, Cotter TW, Salyer RD, Miranpuri GS, Yanez MA, Poulsen CE, DeWolfe JL, Byrne GI. 1999. Prior genital tract infection with a murine or human biovar of *Chlamydia trachomatis* protects mice against heterotypic challenge infection. *Infect Immun* 67:3019–3025.
 75. Ifere GO, He Q, Igietseme JU, Ananaba GA, Lyn D, Lubitz W, Kellar KL, Black CM, Eko FO. 2007. Immunogenicity and protection against genital *Chlamydia* infection and its complications by a multisubunit candidate vaccine. *J Microbiol Immunol Infect* 40:188–200.
 76. Hadad R, Marks E, Kalbina I, Schon K, Unemo M, Lycke N, Strid A, Andersson S. 2016. Protection against genital tract *Chlamydia trachomatis* infection following intranasal immunization with a novel recombinant MOMP VS2/4 antigen. *APMIS* 124:1078–1086. <https://doi.org/10.1111/apm.12605>.
 77. Sturdevant GL, Caldwell HD. 2014. Innate immunity is sufficient for the clearance of *Chlamydia trachomatis* from the female mouse genital tract. *Pathog Dis* 72:70–73. <https://doi.org/10.1111/2049-632X.12164>.
 78. Pal S, Sarcon AK, de la Maza LM. 2009. C3H male mice with severe combined immunodeficiency cannot clear a urethral infection with a human serovar of *Chlamydia trachomatis*. *Infect Immun* 77:5602–5607. <https://doi.org/10.1128/IAI.00766-09>.
 79. Tuffrey M, Falder P, Gale J, Quinn R, Taylor-Robinson D. 1986. Infertility in mice infected genitally with a human strain of *Chlamydia trachomatis*. *J Reprod Fertil* 78:251–260. <https://doi.org/10.1530/jrf.0.0780251>.
 80. Tuffrey M, Falder P, Gale J, Taylor-Robinson D. 1986. Salpingitis in mice induced by human strains of *Chlamydia trachomatis*. *Br J Exp Pathol* 67:605–616.
 81. Tuffrey M, Alexander F, Woods C, Taylor-Robinson D. 1992. Genetic susceptibility to chlamydial salpingitis and subsequent infertility in mice. *J Reprod Fertil* 95:31–38. <https://doi.org/10.1530/jrf.0.0950031>.
 82. Tuffrey M, Alexander F, Taylor-Robinson D. 1990. Severity of salpingitis in mice after primary and repeated inoculation with a human strain of *Chlamydia trachomatis*. *J Exp Pathol (Oxford)* 71:403–410.
 83. Carmichael JR, Tifrea D, Pal S, de la Maza LM. 2013. Differences in infectivity and induction of infertility: a comparative study of *Chlamydia trachomatis* strains in the murine model. *Microbes Infect* 15: 219–229. <https://doi.org/10.1016/j.micinf.2012.12.001>.
 84. Swenson CE, Schachter J. 1984. Infertility as a consequence of chlamydial infection of the upper genital tract in female mice. *Sex Transm Dis* 11:64–67. <https://doi.org/10.1097/00007435-198404000-00002>.
 85. Stary G, Olive A, Radovic-Moreno AF, Gondek D, Alvarez D, Basto PA, Perro M, Vrbancac VD, Tager AM, Shi J, Yethon JA, Farokhzad OC, Langer R, Starnbach MN, von Andrian UH. 2015. A mucosal vaccine against *Chlamydia trachomatis* generates two waves of protective memory T cells. *Science* 348:aaa8205. <https://doi.org/10.1126/science.aaa8205>.
 86. Karunakaran KP, Yu H, Jiang X, Chan Q, Moon KM, Foster LJ, Brunham RC. 2015. Outer membrane proteins preferentially load MHC class II peptides: implications for a *Chlamydia trachomatis* T cell vaccine. *Vaccine* 33:2159–2166. <https://doi.org/10.1016/j.vaccine.2015.02.055>.
 87. Gondek DC, Olive AJ, Stary G, Starnbach MN. 2012. CD4⁺ T cells are necessary and sufficient to confer protection against *Chlamydia trachomatis* infection in the murine upper genital tract. *J Immunol* 189: 2441–2449. <https://doi.org/10.4049/jimmunol.1103032>.
 88. Nelson DE, Virok DP, Wood H, Roshick C, Johnson RM, Whitmire WM, Crane DD, Steele-Mortimer O, Kari L, McClarty G, Caldwell HD. 2005. Chlamydial IFN-gamma immune evasion is linked to host infection tropism. *Proc Natl Acad Sci U S A* 102:10658–10663. <https://doi.org/10.1073/pnas.0504198102>.
 89. Morrison RP, Feilzer K, Tumas DB. 1995. Gene knockout mice establish a primary protective role for major histocompatibility complex class II-restricted responses in *Chlamydia trachomatis* genital tract infection. *Infect Immun* 63:4661–4668.
 90. Morrison SG, Morrison RP. 2001. Resolution of secondary *Chlamydia trachomatis* genital tract infection in immune mice with depletion of both CD4⁺ and CD8⁺ T cells. *Infect Immun* 69:2643–2649. <https://doi.org/10.1128/IAI.69.4.2643-2649.2001>.
 91. Rank RG, Soderberg LS, Barron AL. 1985. Chronic chlamydial genital infection in congenitally athymic nude mice. *Infect Immun* 48:847–849.
 92. Plummer FA, Simonsen JN, Cameron DW, Ndinya-Achola JO, Kreiss JK, Gakinya MN, Waiyaki P, Cheang M, Piot P, Ronald AR, Ngugi EN. 1991. Cofactors in male-female sexual transmission of human immunodeficiency virus type 1. *J Infect Dis* 163:233–239. <https://doi.org/10.1093/infdis/163.2.233>.
 93. Igietseme JU, Magee DM, Williams DM, Rank RG. 1994. Role for CD8⁺ T cells in antichlamydial immunity defined by *Chlamydia*-specific T-lymphocyte clones. *Infect Immun* 62:5195–5197.
 94. Nogueira CV, Zhang X, Giovannone N, Sennott EL, Starnbach MN. 2015. Protective immunity against *Chlamydia trachomatis* can engage both CD4⁺ and CD8⁺ T cells and bridge the respiratory and genital mucosae. *J Immunol* 194:2319–2329. <https://doi.org/10.4049/jimmunol.1402675>.
 95. Johnson RM, Brunham RC. 2016. Tissue-resident T cells as the central paradigm of *Chlamydia* immunity. *Infect Immun* 84:868–873. <https://doi.org/10.1128/IAI.01378-15>.
 96. Morrison SG, Morrison RP. 2000. In situ analysis of the evolution of the primary immune response in murine *Chlamydia trachomatis* genital tract infection. *Infect Immun* 68:2870–2879. <https://doi.org/10.1128/IAI.68.5.2870-2879.2000>.
 97. Schenkel JM, Masopust D. 2014. Tissue-resident memory T cells. *Immunity* 41:886–897. <https://doi.org/10.1016/j.immuni.2014.12.007>.
 98. Park CO, Kupper TS. 2015. The emerging role of resident memory T cells in protective immunity and inflammatory disease. *Nat Med* 21: 688–697. <https://doi.org/10.1038/nm.3883>.
 99. Steinbach K, Vincenti I, Kreutzfeldt M, Page N, Muschaweckh A, Wagner I, Drexler I, Pinschewer D, Korn T, Merkler D. 2016. Brain-resident memory T cells represent an autonomous cytotoxic barrier to viral infection. *J Exp Med* 213:1571–1587. <https://doi.org/10.1084/jem.20151916>.
 100. Morrison SG, Morrison RP. 2005. A predominant role for antibody in acquired immunity to chlamydial genital tract reinfection. *J Immunol* 175:7536–7542. <https://doi.org/10.4049/jimmunol.175.11.7536>.
 101. Naglak EK, Morrison SG, Morrison RP. 6 September 2016. IFN-gamma is required for optimal antibody-mediated immunity against genital *Chlamydia* infection. *Infect Immun* <https://doi.org/10.1128/IAI.00749-16>.
 102. Li LX, McSorley SJ. 2013. B cells enhance antigen-specific CD4 T cell priming and prevent bacteria dissemination following *Chlamydia muridarum* genital tract infection. *PLoS Pathog* 9:e1003707. <https://doi.org/10.1371/journal.ppat.1003707>.
 103. Farris CM, Morrison SG, Morrison RP. 2010. CD4⁺ T cells and antibody are required for optimal major outer membrane protein vaccine-induced immunity to *Chlamydia muridarum* genital infection. *Infect Immun* 78:4374–4383. <https://doi.org/10.1128/IAI.00622-10>.
 104. Igietseme JU, Rank RG. 1991. Susceptibility to reinfection after a primary chlamydial genital infection is associated with a decrease of antigen-specific T cells in the genital tract. *Infect Immun* 59:1346–1351.
 105. Yi Y, Yang X, Brunham RC. 1997. Autoimmunity to heat shock protein

- 60 and antigen-specific production of interleukin-10. *Infect Immun* 65:1669–1674.
106. Morrison RP, Belland RJ, Lyng K, Caldwell HD. 1989. Chlamydial disease pathogenesis. The 57-kD chlamydial hypersensitivity antigen is a stress response protein. *J Exp Med* 170:1271–1283.
 107. Budrys NM, Gong S, Rodgers AK, Wang J, Loudon C, Shain R, Schenken RS, Zhong G. 2012. Chlamydia trachomatis antigens recognized in women with tubal factor infertility, normal fertility, and acute infection. *Obstet Gynecol* 119:1009–1016. <https://doi.org/10.1097/AOG.0b013e3182519326>.
 108. Brunham RC, Kuo CC, Cles L, Holmes KK. 1983. Correlation of host immune response with quantitative recovery of Chlamydia trachomatis from the human endocervix. *Infect Immun* 39:1491–1494.
 109. Cotter TW, Meng Q, Shen ZL, Zhang YX, Su H, Caldwell HD. 1995. Protective efficacy of major outer membrane protein-specific immunoglobulin A (IgA) and IgG monoclonal antibodies in a murine model of Chlamydia trachomatis genital tract infection. *Infect Immun* 63:4704–4714.
 110. Pal S, Bravo J, Peterson EM, de la Maza LM. 2008. Protection of wild-type and severe combined immunodeficiency mice against an intranasal challenge by passive immunization with monoclonal antibodies to the Chlamydia trachomatis mouse pneumonitis major outer membrane protein. *Infect Immun* 76:5581–5587. <https://doi.org/10.1128/IAI.00574-08>.
 111. Pal S, Theodor I, Peterson EM, de la Maza LM. 1997. Monoclonal immunoglobulin A antibody to the major outer membrane protein of the Chlamydia trachomatis mouse pneumonitis biovar protects mice against a chlamydial genital challenge. *Vaccine* 15:575–582. [https://doi.org/10.1016/S0264-410X\(97\)00206-5](https://doi.org/10.1016/S0264-410X(97)00206-5).
 112. Roshick C, Wood H, Caldwell HD, McClarty G. 2006. Comparison of gamma interferon-mediated antichlamydial defense mechanisms in human and mouse cells. *Infect Immun* 74:225–238. <https://doi.org/10.1128/IAI.74.1.225-238.2006>.
 113. Perry LL, Feilzer K, Caldwell HD. 1997. Immunity to Chlamydia trachomatis is mediated by T helper 1 cells through IFN-gamma-dependent and -independent pathways. *J Immunol* 158:3344–3352.
 114. Igietseme JU, Ananaba GA, Bolier J, Bowers S, Moore T, Belay T, Eko FO, Lyn D, Black CM. 2000. Suppression of endogenous IL-10 gene expression in dendritic cells enhances antigen presentation for specific Th1 induction: potential for cellular vaccine development. *J Immunol* 164:4212–4219. <https://doi.org/10.4049/jimmunol.164.8.4212>.
 115. Zhong GM, Peterson EM, Czarniecki CW, Schreiber RD, de la Maza LM. 1989. Role of endogenous gamma interferon in host defense against Chlamydia trachomatis infections. *Infect Immun* 57:152–157.
 116. Cotter TW, Ramsey KH, Miranpuri GS, Poulsen CE, Byrne GI. 1997. Dissemination of Chlamydia trachomatis chronic genital tract infection in gamma interferon gene knockout mice. *Infect Immun* 65:2145–2152.
 117. Pal S, Fielder TJ, Peterson EM, de la Maza LM. 1994. Protection against infertility in a BALB/c mouse salpingitis model by intranasal immunization with the mouse pneumonitis biovar of Chlamydia trachomatis. *Infect Immun* 62:3354–3362.
 118. Pal S, Peterson EM, de la Maza LM. 2003. Induction of protective immunity against a Chlamydia trachomatis genital infection in three genetically distinct strains of mice. *Immunology* 110:368–375. <https://doi.org/10.1046/j.1365-2567.2003.01748.x>.
 119. Pal S, Peterson EM, de la Maza LM. 1996. Intranasal immunization induces long-term protection in mice against a Chlamydia trachomatis genital challenge. *Infect Immun* 64:5341–5348.
 120. Pal S, Peterson EM, de la Maza LM. 2005. Vaccination of newborn mice induces a strong protective immune response against respiratory and genital challenges with Chlamydia trachomatis. *Vaccine* 23:5351–5358. <https://doi.org/10.1016/j.vaccine.2005.06.026>.
 121. Peterson EM, You JZ, Motin V, de la Maza LM. 1999. Intranasal immunization with Chlamydia trachomatis, serovar E, protects from a subsequent vaginal challenge with the homologous serovar. *Vaccine* 17:2901–2907. [https://doi.org/10.1016/S0264-410X\(99\)00131-0](https://doi.org/10.1016/S0264-410X(99)00131-0).
 122. Pal S, Rangel J, Peterson EM, de la Maza LM. 1999. Immunogenic and protective ability of the two developmental forms of Chlamydiae in a mouse model of infertility. *Vaccine* 18:752–761. [https://doi.org/10.1016/S0264-410X\(99\)00032-8](https://doi.org/10.1016/S0264-410X(99)00032-8).
 123. Yu H, Karunakaran KP, Kelly I, Shen C, Jiang X, Foster LJ, Brunham RC. 2011. Immunization with live and dead Chlamydia muridarum induces different levels of protective immunity in a murine genital tract model: correlation with MHC class II peptide presentation and multifunctional Th1 cells. *J Immunol* 186:3615–3621. <https://doi.org/10.4049/jimmunol.1002952>.
 124. Lu C, Zeng H, Li Z, Lei L, Yeh IT, Wu Y, Zhong G. 2012. Protective immunity against mouse upper genital tract pathology correlates with high IFN-gamma but low IL-17 T cell and anti-secretion protein antibody responses induced by replicating chlamydial organisms in the airway. *Vaccine* 30:475–485. <https://doi.org/10.1016/j.vaccine.2011.10.059>.
 125. Coler RN, Bhatia A, Maisonneuve JF, Probst P, Barth B, Ovendale P, Fang H, Alderson M, Lobet Y, Cohen J, Mettens P, Reed SG. 2009. Identification and characterization of novel recombinant vaccine antigens for immunization against genital Chlamydia trachomatis. *FEMS Immunol Med Microbiol* 55:258–270. <https://doi.org/10.1111/j.1574-695X.2008.00527.x>.
 126. Su H, Messer R, Whitmire W, Fischer E, Portis JC, Caldwell HD. 1998. Vaccination against chlamydial genital tract infection after immunization with dendritic cells pulsed ex vivo with nonviable Chlamydiae. *J Exp Med* 188:809–818. <https://doi.org/10.1084/jem.188.5.809>.
 127. Lu H, Zhong G. 1999. Interleukin-12 production is required for chlamydial antigen-pulsed dendritic cells to induce protection against live Chlamydia trachomatis infection. *Infect Immun* 67:1763–1769.
 128. O'Connell CM, Ingalls RR, Andrews CW, Jr, Scurlock AM, Darville T. 2007. Plasmid-deficient Chlamydia muridarum fail to induce immune pathology and protect against oviduct disease. *J Immunol* 179:4027–4034. <https://doi.org/10.4049/jimmunol.179.6.4027>.
 129. Lei L, Chen J, Hou S, Ding Y, Yang Z, Zeng H, Baseman J, Zhong G. 2014. Reduced live organism recovery and lack of hydrosalpinx in mice infected with plasmid-free Chlamydia muridarum. *Infect Immun* 82:983–992. <https://doi.org/10.1128/IAI.01543-13>.
 130. Olivares-Zavaleta N, Whitmire W, Gardner D, Caldwell HD. 2010. Immunization with the attenuated plasmidless Chlamydia trachomatis L2(25667R) strain provides partial protection in a murine model of female genitourinary tract infection. *Vaccine* 28:1454–1462. <https://doi.org/10.1016/j.vaccine.2009.11.073>.
 131. Kari L, Whitmire WM, Olivares-Zavaleta N, Goheen MM, Taylor LD, Carlson JH, Sturdevant GL, Lu C, Bakios LE, Randall LB, Parnell MJ, Zhong G, Caldwell HD. 2011. A live-attenuated chlamydial vaccine protects against trachoma in nonhuman primates. *J Exp Med* 208:2217–2223. <https://doi.org/10.1084/jem.20111266>.
 132. Qu Y, Frazer LC, O'Connell CM, Tarantal AF, Andrews CW, Jr, O'Connor SL, Russell AN, Sullivan JE, Poston TB, Vallejo AN, Darville T. 2015. Comparable genital tract infection, pathology, and immunity in rhesus macaques inoculated with wild-type or plasmid-deficient Chlamydia trachomatis serovar D. *Infect Immun* 83:4056–4067. <https://doi.org/10.1128/IAI.00841-15>.
 133. Sigar IM, Schripsema JH, Wang Y, Clarke IN, Cutcliffe LT, Seth-Smith HM, Thomson NR, Bjartling C, Unemo M, Persson K, Ramsey KH. 2014. Plasmid deficiency in urogenital isolates of Chlamydia trachomatis reduces infectivity and virulence in a mouse model. *Pathog Dis* 70:61–69. <https://doi.org/10.1111/2049-632X.12086>.
 134. Peterson EM, Markoff BA, Schachter J, de la Maza LM. 1990. The 7.5-kb plasmid present in Chlamydia trachomatis is not essential for the growth of this microorganism. *Plasmid* 23:144–148. [https://doi.org/10.1016/0147-619X\(90\)90033-9](https://doi.org/10.1016/0147-619X(90)90033-9).
 135. Igietseme JU, Portis JL, Perry LL. 2001. Inflammation and clearance of Chlamydia trachomatis in enteric and nonenteric mucosae. *Infect Immun* 69:1832–1840. <https://doi.org/10.1128/IAI.69.3.1832-1840.2001>.
 136. Wang SP, Grayston JT. 1963. Classification of trachoma virus strains by protection of mice from toxic death. *J Immunol* 90:849–856.
 137. Wang S-P, Grayston J. 1984. Microimmunofluorescence serology of Chlamydia trachomatis, p 87–118. *In* de la Maza LM, Peterson EM (ed), *Medical virology III*, 1st ed. Elsevier Science Publishers, New York, NY.
 138. Stephens RS, Kalman S, Lammel C, Fan J, Marathe R, Aravind L, Mitchell W, Olinger L, Tatusov RL, Zhao Q, Koonin EV, Davis RW. 1998. Genome sequence of an obligate intracellular pathogen of humans: Chlamydia trachomatis. *Science* 282:754–759. <https://doi.org/10.1126/science.282.5389.754>.
 139. Stephens RS, Sanchez-Pescador R, Wagar EA, Inouye C, Urdea MS. 1987. Diversity of Chlamydia trachomatis major outer membrane protein genes. *J Bacteriol* 169:3879–3885. <https://doi.org/10.1128/jb.169.9.3879-3885.1987>.
 140. Fitch WM, Peterson EM, de la Maza LM. 1993. Phylogenetic analysis of the outer-membrane-protein genes of Chlamydiae, and its implication for vaccine development. *Mol Biol Evol* 10:892–913.

141. Zhang D, Yang X, Berry J, Shen C, McClarty G, Brunham RC. 1997. DNA vaccination with the major outer-membrane protein gene induces acquired immunity to *Chlamydia trachomatis* (mouse pneumonitis) infection. *J Infect Dis* 176:1035–1040. <https://doi.org/10.1086/516545>.
142. Su H, Caldwell HD. 1992. Immunogenicity of a chimeric peptide corresponding to T helper and B cell epitopes of the *Chlamydia trachomatis* major outer membrane protein. *J Exp Med* 175:227–235. <https://doi.org/10.1084/jem.175.1.227>.
143. Su H, Parnell M, Caldwell HD. 1995. Protective efficacy of a parenterally administered MOMP-derived synthetic oligopeptide vaccine in a murine model of *Chlamydia trachomatis* genital tract infection: serum neutralizing IgG antibodies do not protect against chlamydial genital tract infection. *Vaccine* 13:1023–1032. [https://doi.org/10.1016/0264-410X\(95\)00017-U](https://doi.org/10.1016/0264-410X(95)00017-U).
144. Pal S, Barnhart KM, Wei Q, Abai AM, Peterson EM, de la Maza LM. 1999. Vaccination of mice with DNA plasmids coding for the *Chlamydia trachomatis* major outer membrane protein elicits an immune response but fails to protect against a genital challenge. *Vaccine* 17:459–465. [https://doi.org/10.1016/S0264-410X\(98\)00219-9](https://doi.org/10.1016/S0264-410X(98)00219-9).
145. Batteiger BE, Rank RG, Bavoil PM, Soderberg LS. 1993. Partial protection against genital reinfection by immunization of guinea-pigs with isolated outer-membrane proteins of the chlamydial agent of guinea-pig inclusion conjunctivitis. *J Gen Microbiol* 139:2965–2972. <https://doi.org/10.1099/00221287-139-12-2965>.
146. Li Z, Chen C, Chen D, Wu Y, Zhong Y, Zhong G. 2008. Characterization of fifty putative inclusion membrane proteins encoded in the *Chlamydia trachomatis* genome. *Infect Immun* 76:2746–2757. <https://doi.org/10.1128/IAI.00010-08>.
147. Liu X, Afrane M, Clemmer DE, Zhong G, Nelson DE. 2010. Identification of *Chlamydia trachomatis* outer membrane complex proteins by differential proteomics. *J Bacteriol* 192:2852–2860. <https://doi.org/10.1128/JB.01628-09>.
148. Rodgers AK, Budrys NM, Gong S, Wang J, Holden A, Schenken RS, Zhong G. 2011. Genome-wide identification of *Chlamydia trachomatis* antigens associated with tubal factor infertility. *Fertil Steril* 96:715–721. <https://doi.org/10.1016/j.fertnstert.2011.06.021>.
149. Lu C, Holland MJ, Gong S, Peng B, Bailey RL, Mabey DW, Wu Y, Zhong G. 2012. Genome-wide identification of *Chlamydia trachomatis* antigens associated with trachomatous trichiasis. *Invest Ophthalmol Vis Sci* 53:2551–2559. <https://doi.org/10.1167/iovs.11-9212>.
150. Sharma J, Zhong Y, Dong F, Piper JM, Wang G, Zhong G. 2006. Profiling of human antibody responses to *Chlamydia trachomatis* urogenital tract infection using microplates arrayed with 156 chlamydial fusion proteins. *Infect Immun* 74:1490–1499. <https://doi.org/10.1128/IAI.74.3.1490-1499.2006>.
151. Wang J, Zhang Y, Lu C, Lei L, Yu P, Zhong G. 2010. A genome-wide profiling of the humoral immune response to *Chlamydia trachomatis* infection reveals vaccine candidate antigens expressed in humans. *J Immunol* 185:1670–1680. <https://doi.org/10.4049/jimmunol.1001240>.
152. Molina DM, Pal S, Kayala MA, Teng A, Kim PJ, Baldi P, Felgner PL, Liang X, de la Maza LM. 2010. Identification of immunodominant antigens of *Chlamydia trachomatis* using proteome microarrays. *Vaccine* 28:3014–3024. <https://doi.org/10.1016/j.vaccine.2009.12.020>.
153. Cruz-Fisher MI, Cheng C, Sun G, Pal S, Teng A, Molina DM, Kayala MA, Vigil A, Baldi P, Felgner PL, Liang X, de la Maza LM. 2011. Identification of immunodominant antigens by probing a whole *Chlamydia trachomatis* open reading frame proteome microarray using sera from immunized mice. *Infect Immun* 79:246–257. <https://doi.org/10.1128/IAI.00626-10>.
154. Teng A, Cruz-Fisher MI, Cheng C, Pal S, Sun G, Ralli-Jain P, Molina DM, Felgner PL, Liang X, de la Maza LM. 2012. Proteomic identification of immunodominant chlamydial antigens in a mouse model. *J Proteomics* 77:176–186. <https://doi.org/10.1016/j.jprot.2012.08.017>.
155. Finco O, Frigimelica E, Buricchi F, Petracca R, Galli G, Faenzi E, Meoni E, Bonci A, Agnusdei M, Nardelli F, Bartolini E, Scarselli M, Caproni E, Laera D, Zedda L, Skibinski D, Giovannazzi S, Bastone R, Ianni E, Cevenini R, Grandi G, Grifantini R. 2011. Approach to discover T- and B-cell antigens of intracellular pathogens applied to the design of *Chlamydia trachomatis* vaccines. *Proc Natl Acad Sci U S A* 108:9969–9974. <https://doi.org/10.1073/pnas.1101756108>.
156. Patton DL, Teng A, Randall A, Liang X, Felgner PL, de la Maza LM. 2014. Whole genome identification of *C. trachomatis* immunodominant antigens after genital tract infections and effect of antibiotic treatment of pigtailed macaques. *J Proteomics* 108:99–109. <https://doi.org/10.1016/j.jprot.2014.05.009>.
157. Picard MD, Bodmer JL, Gierahn TM, Lee A, Price J, Cohane K, Clemens V, DeVault VL, Gurok G, Kohberger R, Higgins DE, Siber GR, Flechtner JB, Geisler WM. 2015. Resolution of *Chlamydia trachomatis* infection is associated with a distinct T cell response profile. *Clin Vaccine Immunol* 22:1206–1218. <https://doi.org/10.1128/CVI.00247-15>.
158. Follmann F, Olsen AW, Jensen KT, Hansen PR, Andersen P, Theisen M. 2008. Antigenic profiling of a *Chlamydia trachomatis* gene-expression library. *J Infect Dis* 197:897–905. <https://doi.org/10.1086/528378>.
159. Caldwell HD, Kromhout J, Schachter J. 1981. Purification and partial characterization of the major outer membrane protein of *Chlamydia trachomatis*. *Infect Immun* 31:1161–1176.
160. Hatch TP, Vance DW, Jr, Al-Hossainy E. 1981. Identification of a major envelope protein in *Chlamydia* spp. *J Bacteriol* 146:426–429.
161. Sun G, Pal S, Sarcon AK, Kim S, Sugawara E, Nikaido H, Cocco MJ, Peterson EM, de la Maza LM. 2007. Structural and functional analyses of the major outer membrane protein of *Chlamydia trachomatis*. *J Bacteriol* 189:6222–6235. <https://doi.org/10.1128/JB.00552-07>.
162. Hatch TP. 1996. Disulfide cross-linked envelope proteins: the functional equivalent of peptidoglycan in chlamydiae? *J Bacteriol* 178:1–5. <https://doi.org/10.1128/jb.178.1.1-5.1996>.
163. Liechti GW, Kuru E, Hall E, Kalinda A, Brun YV, VanNieuwenhze M, Maurelli AT. 2014. A new metabolic cell-wall labelling method reveals peptidoglycan in *Chlamydia trachomatis*. *Nature* 506:507–510. <https://doi.org/10.1038/nature12892>.
164. Hatch TP, Miceli M, Sublett JE. 1986. Synthesis of disulfide-bonded outer membrane proteins during the developmental cycle of *Chlamydia psittaci* and *Chlamydia trachomatis*. *J Bacteriol* 165:379–385. <https://doi.org/10.1128/jb.165.2.379-385.1986>.
165. Hatch T. 1998. *Chlamydia*: old ideas crushed, new mysteries bared. *Science* 282:638–639. <https://doi.org/10.1126/science.282.5389.638>.
166. Caldwell HD, Pery LJ. 1982. Neutralization of *Chlamydia trachomatis* infectivity with antibodies to the major outer membrane protein. *Infect Immun* 38:745–754.
167. Baehr W, Zhang YX, Joseph T, Su H, Nano FE, Everett KD, Caldwell HD. 1988. Mapping antigenic domains expressed by *Chlamydia trachomatis* major outer membrane protein genes. *Proc Natl Acad Sci U S A* 85:4000–4004. <https://doi.org/10.1073/pnas.85.11.4000>.
168. Ortiz L, Demick KP, Petersen JW, Polka M, Rudersdorf RA, Van der Pol B, Jones R, Angevine M, DeMars R. 1996. *Chlamydia trachomatis* major outer membrane protein (MOMP) epitopes that activate HLA class II-restricted T cells from infected humans. *J Immunol* 157:4554–4567.
169. Pal S, Peterson EM, de la Maza LM. 2005. Vaccination with the *Chlamydia trachomatis* major outer membrane protein can elicit an immune response as protective as that resulting from inoculation with live bacteria. *Infect Immun* 73:8153–8160. <https://doi.org/10.1128/IAI.73.12.8153-8160.2005>.
170. Stephens R, Wagar E, Schoolnik G. 1988. High-resolution mapping of serovar-specific and common antigenic determinants of the major outer membrane protein of *Chlamydia trachomatis*. *J Exp Med* 167:817–831. <https://doi.org/10.1084/jem.167.3.817>.
171. Pal S, Theodor I, Peterson EM, de la Maza LM. 1997. Immunization with an acellular vaccine consisting of the outer membrane complex of *Chlamydia trachomatis* induces protection against a genital challenge. *Infect Immun* 65:3361–3369.
172. Pal S, Theodor I, Peterson EM, de la Maza LM. 2001. Immunization with the *Chlamydia trachomatis* mouse pneumonitis major outer membrane protein can elicit a protective immune response against a genital challenge. *Infect Immun* 69:6240–6247. <https://doi.org/10.1128/IAI.69.10.6240-6247.2001>.
173. Pal S, Tatarenkova OV, de la Maza LM. 2015. A vaccine formulated with the major outer membrane protein can protect C3H/HeN, a highly susceptible strain of mice, from a *Chlamydia muridarum* genital challenge. *Immunology* 146:432–443. <https://doi.org/10.1111/imm.12520>.
174. Sun G, Pal S, Weiland J, Peterson EM, de la Maza LM. 2009. Protection against an intranasal challenge by vaccines formulated with native and recombinant preparations of the *Chlamydia trachomatis* major outer membrane protein. *Vaccine* 27:5020–5025. <https://doi.org/10.1016/j.vaccine.2009.05.008>.
175. Tifrea DF, Sun G, Pal S, Zardeneta G, Cocco MJ, Popot JL, de la Maza LM. 2011. Amphipols stabilize the *Chlamydia* major outer membrane protein and enhance its protective ability as a vaccine. *Vaccine* 29:4623–4631. <https://doi.org/10.1016/j.vaccine.2011.04.065>.

176. Carmichael JR, Pal S, Tifrea D, de la Maza LM. 2011. Induction of protection against vaginal shedding and infertility by a recombinant Chlamydia vaccine. *Vaccine* 29:5276–5283. <https://doi.org/10.1016/j.vaccine.2011.05.013>.
177. Kari L, Whitmire WM, Crane DD, Reveneau N, Carlson JH, Goheen MM, Peterson EM, Pal S, de la Maza LM, Caldwell HD. 2009. Chlamydia trachomatis native major outer membrane protein induces partial protection in nonhuman primates: implication for a trachoma transmission-blocking vaccine. *J Immunol* 182:8063–8070. <https://doi.org/10.4049/jimmunol.0804375>.
178. Hansen J, Jensen KT, Follmann F, Agger EM, Theisen M, Andersen P. 2008. Liposome delivery of Chlamydia muridarum major outer membrane protein primes a Th1 response that protects against genital chlamydial infection in a mouse model. *J Infect Dis* 198:758–767. <https://doi.org/10.1086/590670>.
179. Hickey DK, Aldwell FE, Beagley KW. 2010. Oral immunization with a novel lipid-based adjuvant protects against genital Chlamydia infection. *Vaccine* 28:1668–1672. <https://doi.org/10.1016/j.vaccine.2009.12.010>.
180. Badamchi-Zadeh A, McKay PF, Korber BT, Barinaga G, Walters AA, Nunes A, Gomes JP, Follmann F, Tregoning JS, Shattock RJ. 2016. A multi-component prime-boost vaccination regimen with a consensus MOMP antigen enhances Chlamydia trachomatis clearance. *Front Immunol* 7:162. <https://doi.org/10.3389/fimmu.2016.00162>.
181. Olsen AW, Follmann F, Erneholt K, Rosenkrands I, Andersen P. 2015. Protection against Chlamydia trachomatis infection and upper genital tract pathological changes by vaccine-promoted neutralizing antibodies directed to the VD4 of the major outer membrane protein. *J Infect Dis* 212:978–989. <https://doi.org/10.1093/infdis/jiv137>.
182. Boje S, Olsen AW, Erneholt K, Agerholm JS, Jungersen G, Andersen P, Follmann F. 2016. A multi-subunit Chlamydia vaccine inducing neutralizing antibodies and strong IFN- γ CMI responses protects against a genital infection in minipigs. *Immunol Cell Biol* 94:185–195. <https://doi.org/10.1038/icb.2015.79>.
183. Henderson IR, Lam AC. 2001. Polymorphic proteins of Chlamydia spp.—autotransporters beyond the Proteobacteria. *Trends Microbiol* 9:573–578. [https://doi.org/10.1016/S0966-842X\(01\)02234-X](https://doi.org/10.1016/S0966-842X(01)02234-X).
184. Swanson KA, Taylor LD, Frank SD, Sturdevant GL, Fischer ER, Carlson JH, Whitmire WM, Caldwell HD. 2009. Chlamydia trachomatis polymorphic membrane protein D is an oligomeric autotransporter with a higher-order structure. *Infect Immun* 77:508–516. <https://doi.org/10.1128/IAI.01173-08>.
185. Hsia RC, Pannekoek Y, Ingerowski E, Bavoil PM. 1997. Type III secretion genes identify a putative virulence locus of Chlamydia. *Mol Microbiol* 25:351–359. <https://doi.org/10.1046/j.1365-2958.1997.4701834.x>.
186. Becker E, Hegemann JH. 2014. All subtypes of the Pmp adhesion family are implicated in chlamydial virulence and show species-specific function. *Microbiologyopen* 3:544–556. <https://doi.org/10.1002/mbo3.186>.
187. Tan C, Hsia RC, Shou H, Carrasco JA, Rank RG, Bavoil PM. 2010. Variable expression of surface-exposed polymorphic membrane proteins in in vitro-grown Chlamydia trachomatis. *Cell Microbiol* 12:174–187. <https://doi.org/10.1111/j.1462-5822.2009.01389.x>.
188. Tan C, Hsia RC, Shou H, Haggerty CL, Ness RB, Gaydos CA, Dean D, Scurlock AM, Wilson DP, Bavoil PM. 2009. Chlamydia trachomatis-infected patients display variable antibody profiles against the nine-member polymorphic membrane protein family. *Infect Immun* 77:3218–3226. <https://doi.org/10.1128/IAI.01566-08>.
189. Vasilevsky S, Stojanov M, Greub G, Baud D. 2016. Chlamydial polymorphic membrane proteins: regulation, function and potential vaccine candidates. *Virulence* 7:11–22. <https://doi.org/10.1080/21505594.2015.1111509>.
190. Taylor BD, Darville T, Tan C, Bavoil PM, Ness RB, Haggerty CL. 2011. The role of Chlamydia trachomatis polymorphic membrane proteins in inflammation and sequelae among women with pelvic inflammatory disease. *Infect Dis Obstet Gynecol* 2011:989762. <https://doi.org/10.1155/2011/989762>.
191. Crane DD, Carlson JH, Fischer ER, Bavoil P, Hsia RC, Tan C, Kuo CC, Caldwell HD. 2006. Chlamydia trachomatis polymorphic membrane protein D is a species-common pan-neutralizing antigen. *Proc Natl Acad Sci U S A* 103:1894–1899. <https://doi.org/10.1073/pnas.0508983103>.
192. Paes W, Brown N, Brzozowski AM, Coler R, Reed S, Carter D, Bland M, Kaye PM, Lacey CJ. 2016. Recombinant polymorphic membrane protein D in combination with a novel, second-generation lipid adjuvant protects against intra-vaginal Chlamydia trachomatis infection in mice. *Vaccine* 34:4123–4131. <https://doi.org/10.1016/j.vaccine.2016.06.081>.
193. Karunakaran KP, Rey-Ladino J, Stoyanov N, Berg K, Shen C, Jiang X, Gabel BR, Yu H, Foster LJ, Brunham RC. 2008. Immunoproteomic discovery of novel T cell antigens from the obligate intracellular pathogen Chlamydia. *J Immunol* 180:2459–2465. <https://doi.org/10.4049/jimmunol.180.4.2459>.
194. Inic-Kanada A, Stojanovic M, Schlacher S, Stein E, Belij-Rammerstorfer S, Marinkovic E, Lukic I, Montanaro J, Schuerer N, Bintner N, Kovacevic-Jovanovic V, Krnjaja O, Mayr UB, Lubitz W, Barisani-Asenbauer T. 2015. Delivery of a chlamydial adhesin N-PmpC subunit vaccine to the ocular mucosa using particulate carriers. *PLoS One* 10:e0144380. <https://doi.org/10.1371/journal.pone.0144380>.
195. Dong F, Zhong Y, Arulanandam B, Zhong G. 2005. Production of a proteolytically active protein, chlamydia protease/proteasome-like activity factor, by five different Chlamydia species. *Infect Immun* 73:1868–1872. <https://doi.org/10.1128/IAI.73.3.1868-1872.2005>.
196. Huang Z, Feng Y, Chen D, Wu X, Huang S, Wang X, Xiao X, Li W, Huang N, Gu L, Zhong G, Chai J. 2008. Structural basis for activation and inhibition of the secreted chlamydia protease CPAF. *Cell Host Microbe* 4:529–542. <https://doi.org/10.1016/j.chom.2008.10.005>.
197. Zhong G, Fan P, Ji H, Dong F, Huang Y. 2001. Identification of a chlamydial protease-like activity factor responsible for the degradation of host transcription factors. *J Exp Med* 193:935–942. <https://doi.org/10.1084/jem.193.8.935>.
198. Tang L, Chen J, Zhou Z, Yu P, Yang Z, Zhong G. 2015. Chlamydia-secreted protease CPAF degrades host antimicrobial peptides. *Microbes Infect* 17:402–408. <https://doi.org/10.1016/j.micinf.2015.02.005>.
199. Yang Z, Tang L, Sun X, Chai J, Zhong G. 2015. Characterization of CPAF critical residues and secretion during Chlamydia trachomatis infection. *Infect Immun* 83:2234–2241. <https://doi.org/10.1128/IAI.00275-15>.
200. Yang Z, Tang L, Zhou Z, Zhong G. 2016. Neutralizing antichlamydial activity of complement by chlamydia-secreted protease CPAF. *Microbes Infect* 18:669–674. <https://doi.org/10.1016/j.micinf.2016.07.002>.
201. Yang Z, Tang L, Shao L, Zhang Y, Zhang T, Schenken R, Valdivia R, Zhong G. 2016. The Chlamydia-secreted protease CPAF promotes chlamydial survival in the mouse lower genital tract. *Infect Immun* 84:2697–2702. <https://doi.org/10.1128/IAI.00280-16>.
202. Murthy AK, Chambers JP, Meier PA, Zhong G, Arulanandam BP. 2007. Intranasal vaccination with a secreted chlamydial protein enhances resolution of genital Chlamydia muridarum infection, protects against oviduct pathology, and is highly dependent upon endogenous gamma interferon production. *Infect Immun* 75:666–676. <https://doi.org/10.1128/IAI.01280-06>.
203. Li W, Guentzel MN, Seshu J, Zhong G, Murthy AK, Arulanandam BP. 2007. Induction of cross-serovar protection against genital chlamydial infection by a targeted multisubunit vaccination approach. *Clin Vaccine Immunol* 14:1537–1544. <https://doi.org/10.1128/CVI.00274-07>.
204. Murthy AK, Li W, Guentzel MN, Zhong G, Arulanandam BP. 2011. Vaccination with the defined chlamydial secreted protein CPAF induces robust protection against female infertility following repeated genital chlamydial challenge. *Vaccine* 29:2519–2522. <https://doi.org/10.1016/j.vaccine.2011.01.074>.
205. Li W, Murthy AK, Lanka GK, Chetty SL, Yu JJ, Chambers JP, Zhong G, Forsthuber TG, Guentzel MN, Arulanandam BP. 2013. A T cell epitope-based vaccine protects against chlamydial infection in HLA-DR4 transgenic mice. *Vaccine* 31:5722–5728. <https://doi.org/10.1016/j.vaccine.2013.09.036>.
206. Chaganty BK, Murthy AK, Evani SJ, Li W, Guentzel MN, Chambers JP, Zhong G, Arulanandam BP. 2010. Heat denatured enzymatically inactive recombinant chlamydial protease-like activity factor induces robust protective immunity against genital chlamydial challenge. *Vaccine* 28:2323–2329. <https://doi.org/10.1016/j.vaccine.2009.12.064>.
207. Murphey C, Murthy AK, Meier PA, Neal Guentzel M, Zhong G, Arulanandam BP. 2006. The protective efficacy of chlamydial protease-like activity factor vaccination is dependent upon CD4⁺ T cells. *Cell Immunol* 242:110–117. <https://doi.org/10.1016/j.cellimm.2006.10.002>.
208. Stothard DR, Williams JA, Van Der Pol B, Jones RB. 1998. Identification of a Chlamydia trachomatis serovar E urogenital isolate which lacks the cryptic plasmid. *Infect Immun* 66:6010–6013.
209. Palmer L, Falkow S. 1986. A common plasmid of Chlamydia trachomatis. *Plasmid* 16:52–62. [https://doi.org/10.1016/0147-619X\(86\)90079-X](https://doi.org/10.1016/0147-619X(86)90079-X).
210. Galaldeen A, Taylor AB, Chen D, Schuermann JP, Holloway SP, Hou S, Gong S, Zhong G, Hart PJ. 2013. Structure of the Chlamydia trachomatis

- immunodominant antigen Pgp3. *J Biol Chem* 288:22068–22079. <https://doi.org/10.1074/jbc.M113.475012>.
211. Chen D, Lei L, Lu C, Galaleideen A, Hart PJ, Zhong G. 2010. Characterization of Pgp3, a Chlamydia trachomatis plasmid-encoded immunodominant antigen. *J Bacteriol* 192:6017–6024. <https://doi.org/10.1128/JB.00847-10>.
 212. Li Z, Chen D, Zhong Y, Wang S, Zhong G. 2008. The chlamydial plasmid-encoded virulence factor Pgp3 is secreted into the cytosol of Chlamydia-infected cells. *Infect Immun* 76:3415–3428. <https://doi.org/10.1128/IAI.01377-07>.
 213. Hou S, Dong X, Yang Z, Li Z, Liu Q, Zhong G. 2015. Chlamydial plasmid-encoded virulence factor Pgp3 neutralizes the antichlamydial activity of human cathelicidin LL-37. *Infect Immun* 83:4701–4709. <https://doi.org/10.1128/IAI.00746-15>.
 214. Li Z, Zhong Y, Lei L, Wu Y, Wang S, Zhong G. 2008. Antibodies from women urogenitally infected with *C. trachomatis* predominantly recognized the plasmid protein pgp3 in a conformation-dependent manner. *BMC Microbiol* 8:90. <https://doi.org/10.1186/1471-2180-8-90>.
 215. Donati M, Sambri V, Comanducci M, Di Leo K, Storni E, Giacani L, Ratti G, Cevenini R. 2003. DNA immunization with pgp3 gene of Chlamydia trachomatis inhibits the spread of chlamydial infection from the lower to the upper genital tract in C3H/HeN mice. *Vaccine* 21:1089–1093. [https://doi.org/10.1016/S0264-410X\(02\)00631-X](https://doi.org/10.1016/S0264-410X(02)00631-X).
 216. Li Z, Wang S, Wu Y, Zhong G, Chen D. 2008. Immunization with chlamydial plasmid protein pORF5 DNA vaccine induces protective immunity against genital chlamydial infection in mice. *Sci China C Life Sci* 51:973–980. <https://doi.org/10.1007/s11427-008-0130-9>.
 217. Ripa T, Nilsson PA. 2007. A Chlamydia trachomatis strain with a 377-bp deletion in the cryptic plasmid causing false-negative nucleic acid amplification tests. *Sex Transm Dis* 34:255–256.
 218. Qiu S, Zhang J, Tian Y, Yang Y, Huang H, Yang D, Lu M, Xu Y. 2008. Reduced antigenicity of naturally occurring hepatitis B surface antigen variants with substitutions at the amino acid residue 126. *Intervirology* 51:400–406. <https://doi.org/10.1159/000205265>.
 219. Yu H, Jiang X, Shen C, Karunakaran KP, Jiang J, Rosin NL, Brunham RC. 2010. Chlamydia muridarum T-cell antigens formulated with the adjuvant DDA/TDB induce immunity against infection that correlates with a high frequency of gamma interferon (IFN-gamma)/tumor necrosis factor alpha and IFN-gamma/interleukin-17 double-positive CD4⁺ T cells. *Infect Immun* 78:2272–2282. <https://doi.org/10.1128/IAI.01374-09>.
 220. Yu H, Karunakaran KP, Jiang X, Brunham RC. 2014. Evaluation of a multisubunit recombinant polymorphic membrane protein and major outer membrane protein T cell vaccine against Chlamydia muridarum genital infection in three strains of mice. *Vaccine* 32:4672–4680. <https://doi.org/10.1016/j.vaccine.2014.06.002>.
 221. Yu H, Karunakaran KP, Jiang X, Shen C, Andersen P, Brunham RC. 2012. Chlamydia muridarum T cell antigens and adjuvants that induce protective immunity in mice. *Infect Immun* 80:1510–1518. <https://doi.org/10.1128/IAI.06338-11>.
 222. Cheng C, Jain P, Pal S, Tifrea D, Sun G, Teng AA, Liang X, Felgner PL, de la Maza LM. 2014. Assessment of the role in protection and pathogenesis of the Chlamydia muridarum V-type ATP synthase subunit A (AtpA) (TC0582). *Microbes Infect* 16:123–133. <https://doi.org/10.1016/j.micinf.2013.10.012>.
 223. Igietseme JU, Eko FO, Black CM. 2011. Chlamydia vaccines: recent developments and the role of adjuvants in future formulations. *Expert Rev Vaccines* 10:1585–1596. <https://doi.org/10.1586/erv.11.139>.
 224. Hafner L, Beagley K, Timms P. 2008. Chlamydia trachomatis infection: host immune responses and potential vaccines. *Mucosal Immunol* 1:116–130. <https://doi.org/10.1038/mi.2007.19>.
 225. Vasilevsky S, Greub G, Nardelli-Haeffiger D, Baud D. 2014. Genital Chlamydia trachomatis: understanding the roles of innate and adaptive immunity in vaccine research. *Clin Microbiol Rev* 27:346–370. <https://doi.org/10.1128/CMR.00105-13>.
 226. Liang S, Bulir D, Kaushic C, Mahony J. 11 November 2016. Considerations for the rational design of a Chlamydia vaccine. *Hum Vaccin Immunother* <https://doi.org/10.1080/21645515.2016.1252886>.
 227. Poston TB, Darville T. 1 April 2016. Chlamydia trachomatis: protective adaptive responses and prospects for a vaccine. *Curr Top Microbiol Immunol* https://doi.org/10.1007/82_2016_6.
 228. Tan M, Bavoil PM (ed). 2012. *Intracellular pathogens I: Chlamydiales*. ASM Press, Washington, DC.
 229. Kawa DE, Schachter J, Stephens RS. 2004. Immune response to the Chlamydia trachomatis outer membrane protein PorB. *Vaccine* 22:4282–4286. <https://doi.org/10.1016/j.vaccine.2004.04.035>.
 230. Tsai PY, Hsu MC, Huang CT, Li SY. 2007. Human antibody and antigen response to InCA antibody of Chlamydia trachomatis. *Int J Immunopathol Pharmacol* 20:156–161.
 231. Wang J, Chen L, Chen F, Zhang X, Zhang Y, Baseman J, Perdus S, Yeh IT, Shain R, Holland M, Bailey R, Mabey D, Yu P, Zhong G. 2009. A chlamydial type III-secreted effector protein (Tarp) is predominantly recognized by antibodies from humans infected with Chlamydia trachomatis and induces protective immunity against upper genital tract pathologies in mice. *Vaccine* 27:2967–2980. <https://doi.org/10.1016/j.vaccine.2009.02.095>.
 232. Bulir DC, Liang S, Lee A, Chong S, Simms E, Stone C, Kaushic C, Ashkar A, Mahony JB. 2016. Immunization with chlamydial type III secretion antigens reduces vaginal shedding and prevents fallopian tube pathology following live *C. muridarum* challenge. *Vaccine* 34:3979–3985. <https://doi.org/10.1016/j.vaccine.2016.06.046>.
 233. Barker CJ, Beagley KW, Hafner LM, Timms P. 2008. In silico identification and in vivo analysis of a novel T-cell antigen from Chlamydia, NrdB. *Vaccine* 26:1285–1296. <https://doi.org/10.1016/j.vaccine.2007.12.048>.
 234. Li Z, Lu C, Peng B, Zeng H, Zhou Z, Wu Y, Zhong G. 2012. Induction of protective immunity against Chlamydia muridarum intravaginal infection with a chlamydial glycogen phosphorylase. *PLoS One* 7:e32997. <https://doi.org/10.1371/journal.pone.0033997>.
 235. Fling SP, Sutherland RA, Steele LN, Hess B, D'Orazio SE, Maisonneuve J, Lampe MF, Probst P, Starnbach MN. 2001. CD8⁺ T cells recognize an inclusion membrane-associated protein from the vacuolar pathogen Chlamydia trachomatis. *Proc Natl Acad Sci U S A* 98:1160–1165. <https://doi.org/10.1073/pnas.98.3.1160>.
 236. Lu C, Peng B, Li Z, Lei L, Li Z, Chen L, He Q, Zhong G, Wu Y. 2013. Induction of protective immunity against Chlamydia muridarum intravaginal infection with the chlamydial immunodominant antigen macrophage infectivity potentiator. *Microbes Infect* 15:329–338. <https://doi.org/10.1016/j.micinf.2013.02.001>.
 237. Eko FO, Ekong E, He Q, Black CM, Igietseme JU. 2011. Induction of immune memory by a multisubunit chlamydial vaccine. *Vaccine* 29:1472–1480. <https://doi.org/10.1016/j.vaccine.2010.12.024>.
 238. Eko FO, He Q, Brown T, McMillan L, Ifere GO, Ananaba GA, Lyn D, Lubitz W, Kellar KL, Black CM, Igietseme JU. 2004. A novel recombinant multisubunit vaccine against Chlamydia. *J Immunol* 173:3375–3382. <https://doi.org/10.4049/jimmunol.173.5.3375>.
 239. Levine MM. 2010. *New generation vaccines*, 4th ed. Informa Healthcare USA, Inc., New York, NY.
 240. Plotkin SA, Orenstein WA, Offit PA. 2013. *Vaccines*, 6th ed. Elsevier, New York, NY.
 241. Akira S, Takeda K. 2004. Toll-like receptor signalling. *Nat Rev Immunol* 4:499–511. <https://doi.org/10.1038/nri1391>.
 242. Akira S, Takeda K, Kaisho T. 2001. Toll-like receptors: critical proteins linking innate and acquired immunity. *Nat Immunol* 2:675–680. <https://doi.org/10.1038/90609>.
 243. Akira S, Uematsu S, Takeuchi O. 2006. Pathogen recognition and innate immunity. *Cell* 124:783–801. <https://doi.org/10.1016/j.cell.2006.02.015>.
 244. Janeway CA, Jr. 1989. Approaching the asymptote? Evolution and revolution in immunology. *Cold Spring Harbor Symp Quant Biol* 54:1–13. <https://doi.org/10.1101/SQB.1989.054.01.003>.
 245. Medzhitov R. 2009. Approaching the asymptote: 20 years later. *Immunity* 30:766–775. <https://doi.org/10.1016/j.immuni.2009.06.004>.
 246. Lowy DR, Schiller JT. 2006. Prophylactic human papillomavirus vaccines. *J Clin Invest* 116:1167–1173. <https://doi.org/10.1172/JCI28607>.
 247. Zuckerman JN. 2006. Protective efficacy, immunotherapeutic potential, and safety of hepatitis B vaccines. *J Med Virol* 78:169–177. <https://doi.org/10.1002/jmv.20524>.
 248. Fukui M, Imamura R, Umemura M, Kawabe T, Suda T. 2003. Pathogen-associated molecular patterns sensitize macrophages to Fas ligand-induced apoptosis and IL-1 beta release. *J Immunol* 171:1868–1874. <https://doi.org/10.4049/jimmunol.171.4.1868>.
 249. Greenfield EM, Beidelschies MA, Tatro JM, Goldberg VM, Hise AG. 2010. Bacterial pathogen-associated molecular patterns stimulate biological activity of orthopaedic wear particles by activating cognate Toll-like receptors. *J Biol Chem* 285:32378–32384. <https://doi.org/10.1074/jbc.M110.136895>.
 250. Gust AA, Biswas R, Lenz HD, Rauhut T, Ranf S, Kemmerling B, Gotz F, Glawischig E, Lee J, Felix G, Nurnberger T. 2007. Bacteria-derived peptidoglycans constitute pathogen-associated molecular patterns

- triggering innate immunity in Arabidopsis. *J Biol Chem* 282: 32338–32348. <https://doi.org/10.1074/jbc.M704886200>.
251. Price JC, Bromfield JJ, Sheldon IM. 2013. Pathogen-associated molecular patterns initiate inflammation and perturb the endocrine function of bovine granulosa cells from ovarian dominant follicles via TLR2 and TLR4 pathways. *Endocrinology* 154:3377–3386. <https://doi.org/10.1210/en.2013-1102>.
 252. Seya T, Matsumoto M, Tsuji S, Begum NA, Azuma I, Toyoshima K. 2002. Structural-functional relationship of pathogen-associated molecular patterns: lessons from BCG cell wall skeleton and mycoplasma lipoprotein M161Ag. *Microbes Infect* 4:955–961. [https://doi.org/10.1016/S1286-4579\(02\)01610-6](https://doi.org/10.1016/S1286-4579(02)01610-6).
 253. Sharma P, Dube D, Singh A, Mishra B, Singh N, Sinha M, Dey S, Kaur P, Mitra DK, Sharma S, Singh TP. 2011. Structural basis of recognition of pathogen-associated molecular patterns and inhibition of proinflammatory cytokines by camel peptidoglycan recognition protein. *J Biol Chem* 286:16208–16217. <https://doi.org/10.1074/jbc.M111.228163>.
 254. Pulendran B. 2004. Modulating TH1/TH2 responses with microbes, dendritic cells, and pathogen recognition receptors. *Immunol Res* 29: 187–196. <https://doi.org/10.1385/IR:29:1-3:187>.
 255. Casadevall A, Pirofski LA. 2003. Exploiting the redundancy in the immune system: vaccines can mediate protection by eliciting ‘unnatural’ immunity. *J Exp Med* 197:1401–1404. <https://doi.org/10.1084/jem.20030637>.
 256. Prebeck S, Kirschning C, Durr S, da Costa C, Donath B, Brand K, Redecke V, Wagner H, Miethke T. 2001. Predominant role of Toll-like receptor 2 versus 4 in Chlamydia pneumoniae-induced activation of dendritic cells. *J Immunol* 167:3316–3323. <https://doi.org/10.4049/jimmunol.167.6.3316>.
 257. Bas S, Neff L, Vuillet M, Spenato U, Seya T, Matsumoto M, Gabay C. 2008. The proinflammatory cytokine response to Chlamydia trachomatis elementary bodies in human macrophages is partly mediated by a lipoprotein, the macrophage infectivity potentiator, through TLR2/TLR1/TLR6 and CD14. *J Immunol* 180:1158–1168. <https://doi.org/10.4049/jimmunol.180.2.1158>.
 258. Nagarajan UM, Ojcius DM, Stahl L, Rank RG, Darville T. 2005. Chlamydia trachomatis induces expression of IFN-gamma-inducible protein 10 and IFN-beta independent of TLR2 and TLR4, but largely dependent on MyD88. *J Immunol* 175:450–460. <https://doi.org/10.4049/jimmunol.175.1.450>.
 259. Ouburg S, Lyons JM, Land JA, den Hartog JE, Fennema JS, de Vries HJ, Bruggeman CA, Ito JI, Pena AS, Lundberg PS, Morre SA. 2009. TLR9 KO mice, haplotypes and CPG indices in Chlamydia trachomatis infection. *Drugs Today (Barc)* 45(Suppl B):83–93. <https://doi.org/10.1358/dot.2009.45.2.1322478>.
 260. O’Connell CM, AbdelRahman YM, Green E, Darville HK, Saira K, Smith B, Darville T, Scurlock AM, Meyer CR, Belland RJ. 2011. Toll-like receptor 2 activation by Chlamydia trachomatis is plasmid dependent, and plasmid-responsive chromosomal loci are coordinately regulated in response to glucose limitation by C. trachomatis but not by C. muridarum. *Infect Immun* 79:1044–1056. <https://doi.org/10.1128/IAI.01118-10>.
 261. Massari P, Toussi DN, Tifrea DF, de la Maza LM. 2013. Toll-like receptor 2-dependent activity of native major outer membrane protein proteoforms of Chlamydia trachomatis. *Infect Immun* 81:303–310. <https://doi.org/10.1128/IAI.01062-12>.
 262. Ingalls RR, Rice PA, Qureshi N, Takayama K, Lin JS, Golenbock DT. 1995. The inflammatory cytokine response to Chlamydia trachomatis infection is endotoxin mediated. *Infect Immun* 63:3125–3130.
 263. Cheng C, Jain P, Bettahi I, Pal S, Tifrea D, de la Maza LM. 2011. A TLR2 agonist is a more effective adjuvant for a Chlamydia major outer membrane protein vaccine than ligands to other TLR and NOD receptors. *Vaccine* 29:6641–6649. <https://doi.org/10.1016/j.vaccine.2011.06.105>.
 264. Li W, Murthy AK, Guentzel MN, Chambers JP, Forsthuber TG, Seshu J, Zhong G, Arulanandam BP. 2010. Immunization with a combination of integral chlamydial antigens and a defined secreted protein induces robust immunity against genital chlamydial challenge. *Infect Immun* 78:3942–3949. <https://doi.org/10.1128/IAI.00346-10>.
 265. Murthy AK, Cong Y, Murphey C, Guentzel MN, Forsthuber TG, Zhong G, Arulanandam BP. 2006. Chlamydial protease-like activity factor induces protective immunity against genital chlamydial infection in transgenic mice that express the human HLA-DR4 allele. *Infect Immun* 74: 6722–6729. <https://doi.org/10.1128/IAI.01119-06>.
 266. Tifrea DF, Pal S, Popot JL, Cocco MJ, de la Maza LM. 2014. Increased immunoaccessibility of MOMP epitopes in a vaccine formulated with amphipols may account for the very robust protection elicited against a vaginal challenge with Chlamydia muridarum. *J Immunol* 192: 5201–5213. <https://doi.org/10.4049/jimmunol.1303392>.
 267. Pal S, Peterson EM, Rappuoli R, Ratti G, de la Maza LM. 2006. Immunization with the Chlamydia trachomatis major outer membrane protein, using adjuvants developed for human vaccines, can induce partial protection in a mouse model against a genital challenge. *Vaccine* 24:766–775. <https://doi.org/10.1016/j.vaccine.2005.08.074>.
 268. Cheng C, Pal S, Tifrea D, Jia Z, de la Maza LM. 2014. A vaccine formulated with a combination of TLR2 and TLR9 adjuvants and the recombinant major outer membrane protein elicits a robust immune response and significant protection against a Chlamydia muridarum challenge. *Microbes Infect* 16:244–252. <https://doi.org/10.1016/j.micinf.2013.11.009>.
 269. Cai S, He F, Samra HS, de la Maza LM, Bottazzi ME, Joshi SB, Middaugh CR. 2009. Biophysical and stabilization studies of the Chlamydia trachomatis mouse pneumonitis major outer membrane protein. *Mol Pharm* 6:1553–1561. <https://doi.org/10.1021/mp900110q>.
 270. Schellack C, Prinz K, Egyed A, Fritz JH, Wittmann B, Ginzler M, Swatosch G, Zauner W, Kast C, Akira S, von Gabain A, Buschle M, Lingnau K. 2006. IC31, a novel adjuvant signaling via TLR9, induces potent cellular and humoral immune responses. *Vaccine* 24:5461–5472. <https://doi.org/10.1016/j.vaccine.2006.03.071>.
 271. Riedl K, Riedl R, von Gabain A, Nagy E, Lingnau K. 2008. The novel adjuvant IC31 strongly improves influenza vaccine-specific cellular and humoral immune responses in young adult and aged mice. *Vaccine* 26:3461–3468. <https://doi.org/10.1016/j.vaccine.2008.04.029>.
 272. Olafsdottir TA, Lingnau K, Nagy E, Jonsdottir I. 2009. IC31, a two-component novel adjuvant mixed with a conjugate vaccine enhances protective immunity against pneumococcal disease in neonatal mice. *Scand J Immunol* 69:194–202. <https://doi.org/10.1111/j.1365-3083.2008.02225.x>.
 273. Cheng C, Cruz-Fisher MI, Tifrea D, Pal S, Wize B, de la Maza LM. 2011. Induction of protection in mice against a respiratory challenge by a vaccine formulated with the Chlamydia major outer membrane protein adjuvanted with IC31(R). *Vaccine* 29:2437–2443. <https://doi.org/10.1016/j.vaccine.2011.01.031>.
 274. McGhee JR, Fujihashi K. 2012. Inside the mucosal immune system. *PLoS Biol* 10:e1001397. <https://doi.org/10.1371/journal.pbio.1001397>.
 275. McGhee JR, Mestecky J, Dertzbaugh MT, Eldridge JH, Hirasawa M, Kiyono H. 1992. The mucosal immune system: from fundamental concepts to vaccine development. *Vaccine* 10:75–88. [https://doi.org/10.1016/0264-410X\(92\)90021-B](https://doi.org/10.1016/0264-410X(92)90021-B).
 276. Mestecky J, Russell MW. 2000. Induction of mucosal immune responses in the human genital tract. *FEMS Immunol Med Microbiol* 27:351–355. <https://doi.org/10.1111/j.1574-695X.2000.tb01449.x>.
 277. Mestecky J, Moldoveanu Z, Russell MW. 2005. Immunologic uniqueness of the genital tract: challenge for vaccine development. *Am J Reprod Immunol* 53:208–214. <https://doi.org/10.1111/j.1600-0897.2005.00267.x>.
 278. Parr EL, Parr MB. 1999. Immune responses and protection against vaginal infection after nasal or vaginal immunization with attenuated herpes simplex virus type-2. *Immunology* 98:639–645. <https://doi.org/10.1046/j.1365-2567.1999.00909.x>.
 279. Parr EL, Parr MB, Thapar M. 1988. A comparison of specific antibody responses in mouse vaginal fluid after immunization by several routes. *J Reprod Immunol* 14:165–176. [https://doi.org/10.1016/0165-0378\(88\)90067-8](https://doi.org/10.1016/0165-0378(88)90067-8).
 280. Newsted D, Fallahi F, Golshani A, Azizi A. 2015. Advances and challenges in mucosal adjuvant technology. *Vaccine* 33:2399–2405. <https://doi.org/10.1016/j.vaccine.2015.03.096>.
 281. Thapar MA, Parr EL, Bozzola JJ, Parr MB. 1991. Secretory immune responses in the mouse vagina after parenteral or intravaginal immunization with an immunostimulating complex (ISCOM). *Vaccine* 9:129–133. [https://doi.org/10.1016/0264-410X\(91\)90269-C](https://doi.org/10.1016/0264-410X(91)90269-C).
 282. Kelly KA, Robinson EA, Rank RG. 1996. Initial route of antigen administration alters the T-cell cytokine profile produced in response to the mouse pneumonitis biovar of Chlamydia trachomatis following genital infection. *Infect Immun* 64:4976–4983.
 283. Ralli-Jain P, Tifrea D, Cheng C, Pal S, de la Maza LM. 2010. Enhancement of the protective efficacy of a Chlamydia trachomatis recombinant vaccine by combining systemic and mucosal routes for immunization. *Vaccine* 28:7659–7666. <https://doi.org/10.1016/j.vaccine.2010.09.040>.

284. Barnett SW, Srivastava IK, Kan E, Zhou F, Goodsell A, Cristillo AD, Ferrai MG, Weiss DE, Letvin NL, Montefiori D, Pal R, Vajdy M. 2008. Protection of macaques against vaginal SHIV challenge by systemic or mucosal and systemic vaccinations with HIV-envelope. *AIDS* 22:339–348. <https://doi.org/10.1097/QAD.0b013e3282f3ca57>.
285. Borsutzky S, Ebensen T, Link C, Becker PD, Fiorelli V, Cafaro A, Ensoli B, Guzman CA. 2006. Efficient systemic and mucosal responses against the HIV-1 Tat protein by prime/boost vaccination using the lipopeptide MALP-2 as adjuvant. *Vaccine* 24:2049–2056. <https://doi.org/10.1016/j.vaccine.2005.11.025>.
286. Holmgren J, Czerkinsky C. 2005. Mucosal immunity and vaccines. *Nat Med* 11:S45–S53. <https://doi.org/10.1038/nm1213>.
287. van Ginkel FW, Nguyen HH, McGhee JR. 2000. Vaccines for mucosal immunity to combat emerging infectious diseases. *Emerg Infect Dis* 6:123–132. <https://doi.org/10.3201/eid0602.000204>.
288. Song JH, Nguyen HH, Cuburu N, Horimoto T, Ko SY, Park SH, Czerkinsky C, Kweon MN. 2008. Sublingual vaccination with influenza virus protects mice against lethal viral infection. *Proc Natl Acad Sci U S A* 105:1644–1649. <https://doi.org/10.1073/pnas.0708684105>.
289. McConnell EL, Basit AW, Murdan S. 2008. Colonic antigen administration induces significantly higher humoral levels of colonic and vaginal IgA, and serum IgG compared to oral administration. *Vaccine* 26: 639–646. <https://doi.org/10.1016/j.vaccine.2007.11.071>.
290. Hasegawa H, Ichinohe T, Strong P, Watanabe I, Ito S, Tamura S, Takahashi H, Sawa H, Chiba J, Kurata T, Sata T. 2005. Protection against influenza virus infection by intranasal administration of hemagglutinin vaccine with chitin microparticles as an adjuvant. *J Med Virol* 75: 130–136. <https://doi.org/10.1002/jmv.20247>.
291. Becker PD, Fiorentini S, Link C, Tosti G, Ebensen T, Caruso A, Guzman CA. 2006. The HIV-1 matrix protein p17 can be efficiently delivered by intranasal route in mice using the TLR 2/6 agonist MALP-2 as mucosal adjuvant. *Vaccine* 24:5269–5276. <https://doi.org/10.1016/j.vaccine.2005.11.008>.
292. Mutsch M, Zhou W, Rhodes P, Bopp M, Chen RT, Linder T, Spyr C, Steffen R. 2004. Use of the inactivated intranasal influenza vaccine and the risk of Bell's palsy in Switzerland. *N Engl J Med* 350:896–903. <https://doi.org/10.1056/NEJMoa030595>.
293. He Q, Martinez-Sobrido L, Eko FO, Palese P, Garcia-Sastre A, Lyn D, Okenu D, Banea C, Ananaba GA, Black CM, Igietseme JU. 2007. Live-attenuated influenza viruses as delivery vectors for Chlamydia vaccines. *Immunology* 122:28–37. <https://doi.org/10.1111/j.1365-2567.2007.02608.x>.
294. Igietseme JU, Murdin A. 2000. Induction of protective immunity against Chlamydia trachomatis genital infection by a vaccine based on major outer membrane protein-lipophilic immune response-stimulating complexes. *Infect Immun* 68:6798–6806. <https://doi.org/10.1128/IAI.68.12.6798-6806.2000>.
295. Champion CI, Kickhoefer VA, Liu G, Moniz RJ, Freed AS, Bergmann LL, Vaccari D, Raval-Fernandes S, Chan AM, Rome LH, Kelly KA. 2009. A vault nanoparticle vaccine induces protective mucosal immunity. *PLoS One* 4:e5409. <https://doi.org/10.1371/journal.pone.0005409>.
296. Brown TH, David J, Acosta-Ramirez E, Moore JM, Lee S, Zhong G, Hancock RE, Xing Z, Halperin SA, Wang J. 2012. Comparison of immune responses and protective efficacy of intranasal prime-boost immunization regimens using adenovirus-based and CpG/HH2 adjuvanted-subunit vaccines against genital Chlamydia muridarum infection. *Vaccine* 30:350–360. <https://doi.org/10.1016/j.vaccine.2011.10.086>.
297. Dixit S, Singh SR, Yilma AN, Agee RD, II, Taha M, Dennis VA. 2014. Poly(lactic acid)-poly(ethylene glycol) nanoparticles provide sustained delivery of a Chlamydia trachomatis recombinant MOMP peptide and potentiate systemic adaptive immune responses in mice. *Nanomedicine* 10:1311–1321. <https://doi.org/10.1016/j.nano.2014.02.009>.
298. Jiang P, Du W, Xiong Y, Lv Y, Feng J, Zhu S, Xue X, Chen S, Zhang L. 2015. Hepatitis B virus core antigen as a carrier for Chlamydia trachomatis MOMP multi-epitope peptide enhances protection against genital chlamydial infection. *Oncotarget* 6:43281–43292. <https://doi.org/10.18632/oncotarget.6533>.
299. Jiang J, Liu G, Kickhoefer VA, Rome LH, Li LX, McSorley SJ, Kelly KA. 2017. A protective vaccine against Chlamydia genital infection using vault nanoparticles without an added adjuvant. *Vaccines (Basel)* 5:E3. <https://doi.org/10.3390/vaccines5010003>.
300. Murdin AD, Su H, Manning DS, Klein MH, Parnell MJ, Caldwell HD. 1993. A poliovirus hybrid expressing a neutralization epitope from the major outer membrane protein of Chlamydia trachomatis is highly immunogenic. *Infect Immun* 61:4406–4414.
301. Kalbina I, Wallin A, Lindh I, Engstrom P, Andersson S, Strid K. 2011. A novel chimeric MOMP antigen expressed in Escherichia coli, Arabidopsis thaliana, and Daucus carota as a potential Chlamydia trachomatis vaccine candidate. *Protein Expr Purif* 80:194–202. <https://doi.org/10.1016/j.pep.2011.08.010>.
302. Tuffrey M, Alexander F, Conlan W, Woods C, Ward M. 1992. Heterotypic protection of mice against chlamydial salpingitis and colonization of the lower genital tract with a human serovar F isolate of Chlamydia trachomatis by prior immunization with recombinant serovar L1 major outer-membrane protein. *J Gen Microbiol* 138:1707–1715. <https://doi.org/10.1099/00221287-138-8-1707>.
303. Eko FO, Okenu DN, Singh UP, He Q, Black C, Igietseme JU. 2011. Evaluation of a broadly protective Chlamydia-cholera combination vaccine candidate. *Vaccine* 29:3802–3810. <https://doi.org/10.1016/j.vaccine.2011.03.027>.
304. Tifrea DF, Ralli-Jain P, Pal S, de la Maza LM. 2013. Vaccination with the recombinant major outer membrane protein elicits antibodies to the constant domains and induces cross-serovar protection against intranasal challenge with Chlamydia trachomatis. *Infect Immun* 81: 1741–1750. <https://doi.org/10.1128/IAI.00734-12>.
305. Litman GW, Rast JP, Fugmann SD. 2010. The origins of vertebrate adaptive immunity. *Nat Rev Immunol* 10:543–553. <https://doi.org/10.1038/nri2807>.
306. Bailey M, Christoforidou Z, Lewis MC. 2013. The evolutionary basis for differences between the immune systems of man, mouse, pig and ruminants. *Vet Immunol Immunopathol* 152:13–19. <https://doi.org/10.1016/j.vetimm.2012.09.022>.
307. Dishaw LJ, Litman GW. 2013. Changing views of the evolution of immunity. *Front Immunol* 4:122. <https://doi.org/10.3389/fimmu.2013.00122>.
308. Yue F, Cheng Y, Breschi A, Vierstra J, Wu W, Ryba T, Sandstrom R, Ma Z, Davis C, Pope BD, Shen Y, Pervouchine DD, Djebali S, Thurman RE, Kaul R, Rynes E, Kirilusha A, Marinov GK, Williams BA, Trout D, Amrhein H, Fisher-Aylor K, Antoshechkin I, DeSalvo G, See LH, Fastuca M, Drenkow J, Zaleski C, Dobin A, Prieto P, Lagarde J, Bussotti G, Tanzer A, Denas O, Li K, Bender MA, Zhang M, Byron R, Groudine MT, McCleary D, Pham L, Ye Z, Kuan S, Edsall L, Wu YC, Rasmussen MD, Bansal MS, Kellis M, Keller CA, Morrissey CS, Mishra T, et al. 2014. A comparative encyclopedia of DNA elements in the mouse genome. *Nature* 515:355–364. <https://doi.org/10.1038/nature13992>.
309. Seok J, Warren HS, Cuenca AG, Mindrinos MN, Baker HV, Xu W, Richards DR, McDonald-Smith GP, Gao H, Hennessy L, Finnerty CC, Lopez CM, Honari S, Moore EE, Minei JP, Cuschieri J, Bankey PE, Johnson JL, Sperry J, Nathens AB, Billiar TR, West MA, Jeschke MG, Klein MB, Gamelli RL, Gibran NS, Brownstein BH, Miller-Graziano C, Calvano SE, Mason PH, Cobb JP, Rahme LG, Lowry SF, Maier RV, Moldawer LL, Herndon DN, Davis RW, Xiao W, Tompkins RG, Inflammation Host Response to Injury, Large Scale Collaborative Research Program. 2013. Genomic responses in mouse models poorly mimic human inflammatory diseases. *Proc Natl Acad Sci U S A* 110:3507–3512. <https://doi.org/10.1073/pnas.1222878110>.
310. Mestas J, Hughes CC. 2004. Of mice and not men: differences between mouse and human immunology. *J Immunol* 172:2731–2738. <https://doi.org/10.4049/jimmunol.172.5.2731>.
311. Gibbons DL, Spencer J. 2011. Mouse and human intestinal immunity: same ballpark, different players; different rules, same score. *Mucosal Immunol* 4:148–157. <https://doi.org/10.1038/mi.2010.85>.
312. Bryant CE, Monie TP. 2012. Mice, men and the relatives: cross-species studies underpin innate immunity. *Open Biol* 2:120015. <https://doi.org/10.1098/rsob.120015>.
313. Zschaler J, Schlorke D, Arnhold J. 2014. Differences in innate immune response between man and mouse. *Crit Rev Immunol* 34:433–454.
314. Castle WE, Little CC. 1910. On a modified Mendelian ratio among yellow mice. *Science* 32:868–870. <https://doi.org/10.1126/science.32.833.868>.
315. Rehli M. 2002. Of mice and men: species variations of Toll-like receptor expression. *Trends Immunol* 23:375–378. [https://doi.org/10.1016/S1471-4906\(02\)02259-7](https://doi.org/10.1016/S1471-4906(02)02259-7).
316. Iwasaki A, Medzhitov R. 2015. Control of adaptive immunity by the innate immune system. *Nat Immunol* 16:343–353. <https://doi.org/10.1038/ni.3123>.
317. Warren HS, Fitting C, Hoff E, Adib-Conquy M, Beasley-Topliffe L, Tesini

- B, Liang X, Valentine C, Hellman J, Hayden D, Cavaillon JM. 2010. Resilience to bacterial infection: difference between species could be due to proteins in serum. *J Infect Dis* 201:223–232. <https://doi.org/10.1086/649557>.
318. Zeng M, Nourishirazi E, Guinet E, Nouri-Shirazi M. 2016. The genetic background influences the cellular and humoral immune responses to vaccines. *Clin Exp Immunol* 186:190–204. <https://doi.org/10.1111/cei.12841>.
319. Coler RN, Duthie MS, Hofmeyer KA, Guderian J, Jayashankar L, Vergara J, Rolf T, Misquith A, Laurance JD, Raman VS, Bailor HR, Cauwelaert ND, Reed SJ, Vallur A, Favila M, Orr MT, Ashman J, Ghosh P, Mondal D, Reed SG. 2015. From mouse to man: safety, immunogenicity and efficacy of a candidate leishmaniasis vaccine LEISH-F3+GLA-SE. *Clin Transl Immunology* 4:e35. <https://doi.org/10.1038/cti.2015.6>.
320. Coers J, Starnbach MN, Howard JC. 2009. Modeling infectious disease in mice: co-adaptation and the role of host-specific IFN γ responses. *PLoS Pathog* 5:e1000333. <https://doi.org/10.1371/journal.ppat.1000333>.
321. Al-Zeer MA, Al-Younes HM, Braun PR, Zerrahn J, Meyer TF. 2009. IFN- γ -inducible Irga6 mediates host resistance against *Chlamydia trachomatis* via autophagy. *PLoS One* 4:e4588. <https://doi.org/10.1371/journal.pone.0004588>.
322. Caldwell HD, Wood H, Crane D, Bailey R, Jones RB, Mabey D, Maclean I, Mohammed Z, Peeling R, Roshick C, Schachter J, Solomon AW, Stamm WE, Suchland RJ, Taylor L, West SK, Quinn TC, Belland RJ, McClarty G. 2003. Polymorphisms in *Chlamydia trachomatis* tryptophan synthase genes differentiate between genital and ocular isolates. *J Clin Invest* 111:1757–1769. <https://doi.org/10.1172/JCI17993>.
323. Eisenhauer PB, Lehrer RI. 1992. Mouse neutrophils lack defensins. *Infect Immun* 60:3446–3447.
324. Ganz T, Selsted ME, Szklarek D, Harwig SS, Daher K, Bainton DF, Lehrer RI. 1985. Defensins. Natural peptide antibiotics of human neutrophils. *J Clin Invest* 76:1427–1435.
325. Soehnlein O, Zernecke A, Eriksson EE, Rothfuchs AG, Pham CT, Herwald H, Bidzhekov K, Rottenberg ME, Weber C, Lindbom L. 2008. Neutrophil secretion products pave the way for inflammatory monocytes. *Blood* 112:1461–1471. <https://doi.org/10.1182/blood-2008-02-139634>.
326. van der Veen BS, de Winther MP, Heeringa P. 2009. Myeloperoxidase: molecular mechanisms of action and their relevance to human health and disease. *Antioxid Redox Signal* 11:2899–2937. <https://doi.org/10.1089/ars.2009.2538>.
327. Peschon JJ, Morrissey PJ, Grabstein KH, Ramsdell FJ, Maraskovsky E, Gliniak BC, Park LS, Ziegler SF, Williams DE, Ware CB, Meyer JD, Davison BL. 1994. Early lymphocyte expansion is severely impaired in interleukin 7 receptor-deficient mice. *J Exp Med* 180:1955–1960. <https://doi.org/10.1084/jem.180.5.1955>.
328. Roifman CM, Zhang J, Chitayat D, Sharfe N. 2000. A partial deficiency of interleukin-7R α is sufficient to abrogate T-cell development and cause severe combined immunodeficiency. *Blood* 96:2803–2807.
329. Gordon CJ, Grafton G, Wood PM, Larche M, Armitage RJ. 2001. Modelling the human immune response: can mice be trusted? *Commentary. Curr Opin Pharmacol* 1:431–435. [https://doi.org/10.1016/S1471-4892\(01\)00074-1](https://doi.org/10.1016/S1471-4892(01)00074-1).
330. Martin RM, Lew AM. 1998. Is IgG2a a good Th1 marker in mice? *Immunol Today* 19:49. [https://doi.org/10.1016/S0167-5699\(97\)87499-3](https://doi.org/10.1016/S0167-5699(97)87499-3).
331. Mosmann T, Coffman R. 1989. Th1 and Th2 cells: different patterns of lymphokine secretion lead to different functional properties. *Annu Rev Immunol* 7:145–163. <https://doi.org/10.1146/annurev.iy.07.040189.001045>.
332. Del Prete G, De Carli M, Almerigogna F, Giudizi MG, Biagiotti R, Romagnani S. 1993. Human IL-10 is produced by both type 1 helper (Th1) and type 2 helper (Th2) T cell clones and inhibits their antigen-specific proliferation and cytokine production. *J Immunol* 150:353–360.
333. Farrar JD, Smith JD, Murphy TL, Leung S, Stark GR, Murphy KM. 2000. Selective loss of type I interferon-induced STAT4 activation caused by a minisatellite insertion in mouse Stat2. *Nat Immunol* 1:65–69. <https://doi.org/10.1038/76932>.
334. Carey A, Cunningham K, Andrew D, Hafner L, Timms P, Beagley K. 2011. A comparison of the effects of a chlamydial vaccine administered during or after a *C. muridarum* urogenital infection of female mice. *Vaccine* 29:6505–6513. <https://doi.org/10.1016/j.vaccine.2011.07.012>.
335. Grayston JT, Wang SP, Yang YF, Woolridge RL. 1962. The effect of trachoma virus vaccine on the course of experimental trachoma infection in blind human volunteers. *J Exp Med* 115:1009–1022. <https://doi.org/10.1084/jem.115.5.1009>.
336. Guerra P, Buogo A, Marubini E, Ghione M. 1967. Analysis of clinical and laboratory data of an experiment with trachoma vaccine in Ethiopia. *Am J Ophthalmol* 63(Suppl):1631–1638. [https://doi.org/10.1016/0002-9394\(67\)94156-6](https://doi.org/10.1016/0002-9394(67)94156-6).
337. Bietti GB, Guerra P, Voza R, Felici A, Ghione M, Buogo A, Lolli B, Salomons H, Kebreth Y. 1966. Results of large-scale vaccination against trachoma in East Africa (Ethiopia) 1960–1965. *Am J Ophthalmol* 61:1010–1029. [https://doi.org/10.1016/0002-9394\(66\)90218-2](https://doi.org/10.1016/0002-9394(66)90218-2).
338. de la Maza MA, de la Maza LM. 1995. A new computer model for estimating the impact of vaccination protocols and its application to the study of *Chlamydia trachomatis* genital infections. *Vaccine* 13:119–127. [https://doi.org/10.1016/0264-410X\(95\)80022-6](https://doi.org/10.1016/0264-410X(95)80022-6).
339. Gray RT, Beagley KW, Timms P, Wilson DP. 2009. Modeling the impact of potential vaccines on epidemics of sexually transmitted *Chlamydia trachomatis* infection. *J Infect Dis* 199:1680–1688. <https://doi.org/10.1086/598983>.
340. Owusu-Eduesei K, Jr, Chesson HW, Gift TL, Brunham RC, Bolan G. 2015. Cost-effectiveness of *Chlamydia* vaccination programs for young women. *Emerg Infect Dis* 21:960–968. <https://doi.org/10.3201/eid2106.141270>.
341. O'Meara CP, Armitage CW, Kollipara A, Andrew DW, Trim L, Plenderleith MB, Beagley KW. 2016. Induction of partial immunity in both males and females is sufficient to protect females against sexual transmission of *Chlamydia*. *Mucosal Immunol* 9:1076–1088. <https://doi.org/10.1038/mi.2015.125>.
342. Zhang YX, Stewart SJ, Caldwell HD. 1989. Protective monoclonal antibodies to *Chlamydia trachomatis* serovar- and serogroup-specific major outer membrane protein determinants. *Infect Immun* 57:636–638.
343. Pinto LA, Kemp TJ, Torres BN, Isaacs-Soriano K, Ingles D, Abrahamsen M, Pan Y, Lazcano-Ponce E, Salmeron J, Giuliano AR. 2016. Quadrivalent human papillomavirus (HPV) vaccine induces HPV-specific antibodies in the oral cavity: results from the mid-adult male vaccine trial. *J Infect Dis* 214:1276–1283. <https://doi.org/10.1093/infdis/jiw359>.
344. Hurt L, Nsouli-Maktabi H, Rohrbeck P, Clark LL. 2016. Use of quadrivalent human papillomavirus vaccine and the prevalence of antibodies to vaccine-targeted strains among female service members before and after vaccination. *MSMR* 23(2):6–13.
345. Jaiyeoba O, Soper DE. 2011. A practical approach to the diagnosis of pelvic inflammatory disease. *Infect Dis Obstet Gynecol* 2011:753037. <https://doi.org/10.1155/2011/753037>.
346. Hines CD, Wang S, Meng X, Skinner JM, Heinrichs JH, Smith JG, Bodicker MA. 2016. MRI as a novel in vivo approach for assessing structural changes of *Chlamydia* pathology in a mouse model. *PLoS One* 11:e0160055. <https://doi.org/10.1371/journal.pone.0160055>.
347. Tukeva TA, Aronen HJ, Karjalainen PT, Molander P, Paavonen T, Paavonen J. 1999. MR imaging in pelvic inflammatory disease: comparison with laparoscopy and US. *Radiology* 210:209–216. <https://doi.org/10.1148/radiology.210.1.r99ja04209>.
348. Sperling R, Kraus TA, Ding J, Veretennikova A, Lorde-Rollins E, Singh T, Lo Y, Quayle AJ, Chang TL. 2013. Differential profiles of immune mediators and in vitro HIV infectivity between endocervical and vaginal secretions from women with *Chlamydia trachomatis* infection: a pilot study. *J Reprod Immunol* 99:80–87. <https://doi.org/10.1016/j.jri.2013.07.003>.
349. Deruaz M, Luster AD. 2015. Chemokine-mediated immune responses in the female genital tract mucosa. *Immunol Cell Biol* 93:347–354. <https://doi.org/10.1038/icb.2015.20>.
350. Darville T, Pelvic Inflammatory Disease Workshop Proceedings Committee. 2013. Pelvic inflammatory disease: identifying research gaps—proceedings of a workshop sponsored by Department of Health and Human Services/National Institutes of Health/National Institute of Allergy and Infectious Diseases, November 3–4, 2011. *Sex Transm Dis* 40:761–767. <https://doi.org/10.1097/OLQ.0000000000000028>.